Track market-moving stories before they get noisy

Compass Wealth Management LLC reduced its holdings in shares of Danaher Corporation (NYSE:DHR – Free Report) by 9.2% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 44,242 shares of the conglomerate’s stock after selling 4,464 shares during the period. Danaher comprises approximately 1.9% of Compass Wealth Management LLC’s portfolio, making the stock its 11th biggest holding. Compass Wealth Management LLC’s holdings in Danaher were worth $9,802,000 at the end of the most recent quarter.

Other large investors have also recently made changes to their positions in the company. Prime Capital Investment Advisors LLC boosted its stake in shares of Danaher by 0.5% in the 3rd quarter. Prime Capital Investment Advisors LLC now owns 9,203 shares of the conglomerate’s stock valued at $2,039,000 after purchasing an additional 45 shares in the last quarter. Veery Capital LLC grew its holdings in shares of Danaher by 3.1% during the 3rd quarter. Veery Capital LLC now owns 1,581 shares of the conglomerate’s stock valued at $350,000 after purchasing an additional 48 shares during the last quarter. Studio Investment Management LLC raised its position in Danaher by 3.3% in the 2nd quarter. Studio Investment Management LLC now owns 1,581 shares of the conglomerate’s stock worth $302,000 after purchasing an additional 51 shares during the period. OLD Second National Bank of Aurora raised its position in Danaher by 0.5% in the 1st quarter. OLD Second National Bank of Aurora now owns 12,114 shares of the conglomerate’s stock worth $2,297,000 after purchasing an additional 57 shares during the period. Finally, Adelphi Trust Co raised its position in Danaher by 2.5% in the 3rd quarter. Adelphi Trust Co now owns 2,365 shares of the conglomerate’s stock worth $524,000 after purchasing an additional 57 shares during the period. 79.05% of the stock is owned by hedge funds and other institutional investors.

Danaher News Roundup Here are the key news stories impacting Danaher this week:

Positive Sentiment: Danaher reported third-quarter adjusted earnings of $2.11 per share, ahead of the $1.92 analyst consensus, while revenue increased 8.3% year over year to $6.55 billion. Biotechnology profitability and improving demand across several end markets supported the earnings beat. Danaher Beats Profit Estimates, Raises Outlook as Customer Demand Improves Positive Sentiment: Management raised its full-year 2026 adjusted EPS outlook to $8.57-$8.62, and biotechnology orders grew at a mid-teens rate. The company also highlighted margin expansion, improving customer demand, and artificial-intelligence capabilities that could support longer-term drug-discovery growth. Danaher: 3 Key Takeaways for Long-Term Investors Positive Sentiment: Several analysts raised their price targets, including TD Cowen and JPMorgan to $270, Goldman Sachs to $275, and Stifel to $260. The upgrades reflect confidence in the earnings beat, improved execution, and the stronger profit outlook. Neutral Sentiment: New CEO Julie Montgomery emphasized the need to improve execution and innovation. Investors are watching whether management can convert the company’s AI and biotechnology investments into sustained growth. Danaher Posts First Earnings Under New CEO Negative Sentiment: Revenue was approximately in line with, or slightly below, estimates, while analysts cited tariff pressure and a cautious 2027 outlook. At roughly 41 times earnings, Danaher’s valuation leaves limited room for operational disappointment, contributing to the negative investor reaction despite the quarterly beat. Wall Street Analysts Forecast Growth Several analysts have weighed in on the stock. JPMorgan Chase & Co. boosted their price target on shares of Danaher from $250.00 to $270.00 and gave the stock an “overweight” rating in a research note on Thursday. Deutsche Bank Aktiengesellschaft reissued a “buy” rating and issued a $240.00 target price on shares of Danaher in a research note on Wednesday, July 22nd. The Goldman Sachs Group restated a “buy” rating and set a $275.00 target price on shares of Danaher in a report on Thursday. Robert W. Baird raised their price target on Danaher from $246.00 to $254.00 and gave the stock an “outperform” rating in a research report on Thursday. Finally, Morgan Stanley lifted their price target on Danaher from $220.00 to $240.00 and gave the stock an “overweight” rating in a research note on Monday, October 12th. One analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and four have given a Hold rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $242.91. View Our Latest Stock Report on Danaher

Danaher Trading Down 1.7% Shares of DHR opened at $229.86 on Friday. The stock has a market capitalization of $161.59 billion, a P/E ratio of 40.83, a PEG ratio of 2.95 and a beta of 0.76. The company has a quick ratio of 1.25, a current ratio of 1.65 and a debt-to-equity ratio of 0.48. The firm has a fifty day simple moving average of $215.76 and a two-hundred day simple moving average of $197.12. Danaher Corporation has a twelve month low of $160.93 and a twelve month high of $242.80.

Danaher (NYSE:DHR – Get Free Report) last announced its quarterly earnings results on Wednesday, October 21st. The conglomerate reported $2.11 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.92 by $0.19. Danaher had a net margin of 16.91% and a return on equity of 11.22%. The business had revenue of $6.55 billion for the quarter, compared to analyst estimates of $6.56 billion. During the same quarter last year, the firm earned $1.89 EPS. The company’s revenue was up 8.3% on a year-over-year basis. On average, research analysts anticipate that Danaher Corporation will post 8.51 EPS for the current year.

Danaher Dividend Announcement The firm also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be paid a $0.40 dividend. The ex-dividend date of this dividend is Wednesday, September 30th. This represents a $1.60 annualized dividend and a dividend yield of 0.7%. Danaher’s dividend payout ratio (DPR) is presently 28.42%.

Danaher Company Profile (Free Report)

Danaher Corporation (NYSE: DHR) is a global science and technology company that develops products, services and solutions for the life sciences, biotechnology and diagnostics markets. Its offerings help researchers, pharmaceutical and biotechnology companies, healthcare providers and other organizations conduct scientific research, develop and manufacture medicines, and diagnose disease.

The company operates through businesses that provide bioprocessing equipment and technologies, laboratory instruments, consumables, analytical tools and clinical diagnostic systems.

Featured Articles Five stocks we like better than Danaher Is Texas Instruments Setting Up for Its Next Big Breakout? Pegasystems’ Q3 Miss Exposed the Problem Standing Between AI and Cash Flow Lam Research’s Earnings Beat Wasn’t the Real Story—Its 2027 Outlook Was Tesla’s Flying-Car Hype Hits an Earnings Reality Check Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Corporation (NYSE:DHR – Free Report).

Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.

Investors interested in Medical Services stocks are likely familiar with Labcorp Holdings (LH - Free Report) and Danaher (DHR - Free Report) . But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out.

We have found that the best way to discover great value opportunities is to pair a strong Zacks Rank with a great grade in the Value category of our Style Scores system. The Zacks Rank favors stocks with strong earnings estimate revision trends, and our Style Scores highlight companies with specific traits.

Both Labcorp Holdings and Danaher have a Zacks Rank of #2 (Buy) right now. The Zacks Rank favors stocks that have recently seen positive revisions to their earnings estimates, so investors should rest assured that both of these companies have improving earnings outlooks. But this is just one piece of the puzzle for value investors.

Value investors also try to analyze a wide range of traditional figures and metrics to help determine whether a company is undervalued at its current share price levels.

The Style Score Value grade factors in a variety of key fundamental metrics, including the popular P/E ratio, P/S ratio, earnings yield, cash flow per share, and a number of other key stats that are commonly used by value investors.

LH currently has a forward P/E ratio of 17.67, while DHR has a forward P/E of 27.42. We also note that LH has a PEG ratio of 1.85. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. DHR currently has a PEG ratio of 2.94.

Another notable valuation metric for LH is its P/B ratio of 3.08. The P/B ratio pits a stock's market value against its book value, which is defined as total assets minus total liabilities. For comparison, DHR has a P/B of 3.13.

Based on these metrics and many more, LH holds a Value grade of B, while DHR has a Value grade of C.

Both LH and DHR are impressive stocks with solid earnings outlooks, but based on these valuation figures, we feel that LH is the superior value option right now.

Revenue: Q3 2026 sales of $6.6 billion.Core Revenue Growth: Up 3% overall; up 5.5% excluding respiratory revenue (100 bps acceleration from Q2).Respiratory Reve

Better-than-expected quarterly profitability was the engine driving Danaher (DHR +4.29%) stock higher on Tuesday. Cheered by the company's estimates-beating results, investors piled into the healthcare conglomerate's equity, and the stock closed the day more than 4% higher.

Healthy improvementsDanaher's total sales in its third quarter amounted to $6.55 billion, up 8% from the year-ago period. Net income under generally accepted accounting principles (GAAP) rose more steeply, growing by 36% to over $1.2 billion. On a non-GAAP (adjusted), per-share basis, net income advanced by 12% to $2.11.

Profitability was boosted by two discrete items: a tariff refund that added $0.06 per share to adjusted profitability, and a $263 million tax settlement and reserve release that padded GAAP net income.

Image source: Getty Images.

Danaher's top-line figure was basically in line with the consensus analyst estimate. Those prognosticators expected $1.92 per share in adjusted net profit.

In its earnings release, the company attributed its gains to "continued acceleration" in its core businesses, with the exception of its seasonal respiratory diagnostics products.

DHR Danaher$233.86+$9.62 (+4.29%)

NYSE · As of 4:00 PM ET 10/21/26

Earnings guidance liftedCompounding that strong earnings beat, Danaher raised its profitability guidance for the entirety of 2026. Management now expects adjusted earnings per share (EPS) to land at $8.57 to $8.62, up from its previous projection of $8.45 to $8.60. It left its adjusted core revenue growth forecast unchanged, at 4% to 5% over the 2025 figure.

Recently, Danaher -- always something of a conglomerate in transition -- finalized a portfolio adjustment process. This has resulted in a leaner, more effective collection of productive assets. The third-quarter sales growth and the confident earnings guidance raise indicate that the strategy is not only working but can continue to drive future improvements. I'm not surprised that investors piled into the stock after earnings.

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Danaher. The Motley Fool has a disclosure policy.

On its third-quarter 2026 earnings call, held on Oct. 21, 2026, Danaher (DHR +3.30%) raised its full-year earnings per share (EPS) guidance following higher third-quarter core revenue growth. For long-term investors, the performance signals accelerating demand across core bioprocessing and clinical diagnostic markets.

Three takeaways from management's comments stand out.

1. Management Shifts Focus From Portfolio Restructuring to Organic GrowthDanaher completed significant portfolio reshaping over recent years to build leadership positions across life sciences and diagnostics. Management's primary focus now moves to selling more effectively across operating units to gain market share.

With that portfolio transformation largely complete, our focus is shifting from reshaping the portfolio to delivering more growth from the businesses we own.
-- Julie Sawyer Montgomery, President and Chief Executive Officer2. Bioprocessing Orders Accelerate as Biopharma Demand RecoversBiomanufacturing customers are expanding production as new therapies advance, driving higher demand for upstream consumables and scientific reagents. That commercial momentum created mid-single-digit sales growth and double-digit order acceleration in some portions of the biotechnology segment.

Orders grew mid-teens in the quarter, with particular strength in both upstream consumables as well as reagents.
-- Matt Gugino, Executive Vice President and Chief Financial Officer3. Capital Allocation Prioritizes Strategically Compounding AcquisitionsManagement maintains mergers and acquisitions (M&A) as its primary tool to deploy capital and compound long-term returns. The company's acquiring specialized platforms like StatLab to expand pathology workflows while preserving strict investment hurdles.

We will maintain the robust investment criteria that has served us well for many decades while bringing strategic clarity and discipline to how we allocate capital and resources.
-- Julie Sawyer Montgomery, President and Chief Executive OfficerLooking AheadRevenue momentum continues across all three operating segments as core end markets recover. Danaher's competitive positioning relies on deep customer intimacy, broad workflow capabilities, and the Danaher Business System (DBS), its standard operating principles for continuous improvement. Executive attention remains fixed on commercial execution, bioprocessing order velocity, and the integration of artificial intelligence (AI) into lab workflows.

Our third quarter came in ahead of our expectations on both the top and bottom line, with Biotechnology, Life Sciences, and Diagnostics core revenue, excluding respiratory revenue, all growing mid-single digits or better.
-- Julie Sawyer Montgomery, President and Chief Executive OfficerManagement expects core revenue growth, excluding respiratory products, to land between 4% and 5% heading into 2027. Combining DBS operational discipline with higher-margin diagnostic and life science offerings keeps the business positioned for durable long-term expansion.

While realizing the full potential of these opportunities will take time, I am confident that with DBS as our foundation, we are uniquely positioned to turn those opportunities into results for our customers and the patients they serve, our associates, and our shareholders.
-- Julie Sawyer Montgomery, President and Chief Executive OfficerThe Motley Fool has positions in and recommends Danaher. The Motley Fool has a disclosure policy.

The Often-Missed Corner of Healthcare That Wall Street Is LovingDanaher NYSE: DHR reported third-quarter 2026 results that exceeded its expectations, citing improved market conditions, commercial execution and operational performance across its Biotechnology, Life Sciences and Diagnostics businesses.

Sales totaled $6.6 billion for the quarter. Core revenue growth excluding respiratory testing revenue was 5.5%, accelerating 100 basis points from the second quarter. Respiratory revenue created an approximately 250-basis-point headwind, resulting in reported core revenue growth of 3%.

Get Danaher alerts:

An AI Play Hiding in Plain Sight: A Look at Johnson ControlsAdjusted operating profit margin rose 110 basis points to 29%, aided primarily by operational execution and a modest benefit from tariff refunds received during the quarter. Adjusted diluted earnings per share increased about 11.5% to $2.11. The company generated $1.6 billion of free cash flow in the quarter and $4 billion through the first nine months of the year.

New CEO Outlines Growth Priorities
President and Chief Executive Officer Julie Sawyer Montgomery, in her first earnings call as CEO, said the company’s objective is to become the “defining leader in Life Sciences and Diagnostics” by gaining share more consistently, delivering profitable growth and helping customers improve patient outcomes.

3 Stocks Offering Strong Value and StabilityMontgomery said Danaher’s focus is shifting from portfolio reshaping toward generating more growth from its existing businesses. She outlined four strategic priorities: commercial excellence, innovation, talent and disciplined capital allocation.

The company’s most immediate opportunity is commercial execution, according to Montgomery. She said Danaher intends to preserve the customer intimacy and accountability of its operating-company structure while making it easier for customers to access capabilities across the broader organization.

In Diagnostics, she said coordinated engagement by leaders from different businesses with major customers has created “several hundred millions of dollars of opportunity” in a short period. Montgomery said Danaher views higher core growth, profitable core growth and “unambiguous share gain” as the measures of progress.

Montgomery also emphasized artificial intelligence as an opportunity both internally and for customers. Danaher recently announced an AI-powered autonomous laboratory at Abcam that combines AI, robotics and technologies from Cytiva, Beckman Coulter Life Sciences, Genedata, IDT and Molecular Devices. The company said the connected design, make and test workflow is designed to help researchers move from an idea to a validated reagent up to eight times faster and produce up to 10 times higher volume than existing models.

The company also announced a collaboration with NVIDIA focused on connecting Danaher instruments, automation and software with NVIDIA AI and advanced-computing capabilities. Montgomery said the company is also working with Anthropic on standards intended to make instruments easier to connect with other agents and instruments.

Segment Performance
Biotechnology core revenue increased 5% in the third quarter. Bioprocessing revenue grew toward the upper end of the mid-single-digit range, exceeding the company’s expectations. Consumables increased mid-single digits, led by upstream consumables, while equipment revenue grew low single digits. Bioprocessing orders increased in the mid-teens, led by upstream consumables and reagents.

Chief Financial Officer Matt Gugino said Danaher maintained its expectation for mid-single-digit bioprocessing core revenue growth for the full year. He said the company continues to view bioprocessing as a long-term high-single-digit growth business, supported by commercial production activity and a pipeline of new programs.

Life Sciences core revenue rose 4.5%. Pall’s applied filtration business grew mid-single digits, driven by aerospace and microelectronics demand. Life Sciences instruments also increased mid-single digits, with SCIEX benefiting from pharma and biopharma demand, improving U.S. academic spending and momentum for products including the ZenoTOF 8600.

Beckman Coulter Life Sciences reported strong performance, including increased demand for AI-enabled automation solutions and services. Collectively, Life Sciences consumables businesses grew low single digits, with IDT benefiting from molecular residual disease and next-generation sequencing products, while Abcam experienced improving academic demand and traction with pharma and biopharma customers.

Diagnostics core revenue excluding respiratory testing increased 7%. Respiratory revenue represented an approximately 650-basis-point headwind, leaving total segment core growth of 50 basis points. Clinical Diagnostics businesses grew mid-single digits, led by Leica Biosystems’ momentum in digital pathology and advanced staining. Beckman Coulter Diagnostics delivered its highest core-growth quarter in more than two years, according to the company.

Cepheid’s non-respiratory molecular diagnostics business grew low double digits, driven by group A strep, virology and sexual-health assays. Respiratory revenue was approximately $350 million, declining year over year due mainly to lower global infection rates, though it was modestly above the company’s expectations as customers purchased ahead of the respiratory season.

Outlook and Capital Deployment
For the fourth quarter, Danaher expects core revenue growth excluding respiratory revenue of 4% to 5%. Respiratory revenue is expected to be an approximately 150-basis-point headwind, while adjusted operating profit margin is projected at about 29.5%.

The company increased its full-year 2026 adjusted diluted EPS guidance to $8.57 to $8.62, from a prior range of $8.45 to $8.60. Gugino said the new range reflects third-quarter outperformance and represents double-digit year-over-year EPS growth.

For 2027, Danaher said it views 4% to 5% core revenue growth excluding respiratory revenue as the appropriate starting point based on current market conditions, though formal guidance will be provided in January. The company is using $1.5 billion in respiratory revenue as its planning assumption for both 2026 and as a starting point for 2027, while noting that seasonal flu variability can affect that figure.

On acquisitions, Montgomery said M&A remains Danaher’s preferred capital-allocation approach and that the company will continue to seek strategically compounding transactions under its established investment criteria. She said Masimo and StatLab, which Leica Biosystems acquired in early fourth quarter, are examples of acquisitions intended to strengthen the Diagnostics platform rather than signal a broader move into medical technology.

Masimo delivered high-single-digit revenue growth in its first full quarter as part of Danaher, according to Montgomery. She said integration is progressing with cost-savings and commercial-synergy opportunities, while Masimo recently received FDA clearance for its smartSET platform to help detect atrial fibrillation.

Danaher also said reshoring activity in bioprocessing is currently centered on brownfield projects, while larger greenfield projects remain largely in planning stages. Montgomery said the company sees the opportunity as potentially reaching $1 billion in the U.S., with the more significant revenue impact expected to begin in 2028 and develop over several years.

About Danaher (NYSE:DHR)Danaher Corporation NYSE: DHR is a global science and technology company that develops products, services and solutions for the life sciences, biotechnology and diagnostics markets. Its offerings help researchers, pharmaceutical and biotechnology companies, healthcare providers and other organizations conduct scientific research, develop and manufacture medicines, and diagnose disease.

The company operates through businesses that provide bioprocessing equipment and technologies, laboratory instruments, consumables, analytical tools and clinical diagnostic systems.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].

Should You Invest $1,000 in Danaher Right Now?Before you consider Danaher, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Danaher wasn't on the list.

While Danaher currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Key Takeaways Danaher's Q3 adjusted EPS rose 11.6% to $2.11, beating estimates by 9.9%.Diagnostics sales jumped 17%, driven by acquisitions, while core sales excluding respiratory testing rose 7%.Danaher raised 2026 adjusted EPS guidance to $8.57-$8.62, targeting 2.5% core revenue growth.
Danaher Corporation (DHR - Free Report) reported third-quarter 2026 adjusted earnings of $2.11 per share, beating the Zacks Consensus Estimate of $1.92 by 9.9%. The bottom line increased 11.6% year over year from $1.89 per share. Stronger profitability in the Biotechnology segment supported results.

Revenues of $6.55 billion were in line with the consensus estimate of $6.55 billion and grew 8.5% year over year. Core sales rose 3.0%, while core sales excluding respiratory testing advanced 5.5%. Acquisitions contributed to reported growth, led by the Diagnostics segment.

DHR’s Segmental PerformanceRevenues from the Biotechnology segment totaled $1.81 billion, up 0.5% year over year from $1.80 billion. Core sales rose 5.0%. Adjusted operating profit increased to $756 million from $669 million, while adjusted operating margin expanded 460 basis points to 41.8%. The segment’s reported operating profit rose to $477 million from $352 million.

Life Sciences revenues were $1.87 billion, up 4.0% from $1.79 billion in the prior-year quarter. Core sales increased 4.5%. Adjusted operating profit climbed to $404 million from $376 million, and adjusted operating margin improved 70 basis points to 21.7%. Reported operating profit increased to $259 million from $222 million.

Diagnostics sales totaled $2.88 billion, increasing 17.0% from $2.46 billion a year earlier. Acquisitions contributed 16.5 percentage points to reported growth. Core sales edged up 0.5%, but core sales excluding respiratory testing increased 7.0%. Adjusted operating profit increased to $831 million from $728 million, although adjusted margin narrowed 80 basis points to 28.8%.

Danaher’s Revenue Growth DriversThe acquisition-led expansion in the Diagnostics segment contrasted with the relatively modest growth in underlying respiratory-related testing. Respiratory testing revenues were approximately $350 million compared with about $500 million in the year-ago period. The decline remained a headwind to overall core growth.

At the company level, acquisitions and divestitures contributed 6.5% to reported sales growth.

DHR’s Cost and Margin ProfileDanaher’s cost of sales rose 7.4% year over year to $2.72 billion. Gross profit increased 8.9% to $3.84 billion, with gross margin of 58.5% compared with 58.2% a year earlier. Selling, general and administrative expenses increased 8.4% to $2.16 billion.

Research and development expenses rose 14.6% to $433 million. Operating profit increased 7.9% to $1.25 billion, while reported operating margin slipped to 19.0% from 19.1%. Adjusted operating profit rose to $1.90 billion from $1.69 billion, lifting adjusted operating margin to 29.0% from 27.9%.

DHR’s Balance Sheet & Cash FlowExiting the third quarter, DHR had cash and equivalents of $5.68 billion compared with $4.62 billion at 2025-end. Long-term debt was $24.39 billion at the end of the quarter compared with $18.42 billion at the end of December 2025.

Danaher generated net cash of $4.74 billion from operating activities in the first nine months of 2026 compared with $4.30 billion in the previous year’s comparable period. Capital expenditures totaled $761 million in the same period, down 3.1% year over year. Free cash flow increased 13.0% year over year to $3.98 billion in the first nine months of 2026.

In the same period, DHR paid out dividends of $790 million, up 21.2% on a year-over-year basis.

DHR Raises 2026 Earnings OutlookFor the fourth quarter of 2026, Danaher projects core revenue growth, excluding respiratory testing, of 4.0-5.0% year over year. Respiratory revenues are expected to create a headwind of roughly 150 basis points, resulting in anticipated overall core sales growth of approximately 3.0%. Adjusted operating margin is projected at about 29.5%.

For full-year 2026, Danaher raised its adjusted earnings guidance to $8.57-$8.62 per share from the prior range of $8.45-$8.60. The company expects full-year core revenue growth of about 2.5%, with mid-single-digit growth excluding respiratory testing. Its Life Sciences business is forecast to deliver 3.0-4.0% core sales growth for the year.

DHR’s Zacks RankThe company currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Other Stocks to ConsiderHere are some other companies within the broader Medical sector, which according to our model, have the right combination of elements to beat on earnings in this reporting cycle.

Acadia Healthcare Company, Inc. (ACHC - Free Report) has an Earnings ESP of +4.84% and a Zacks Rank of 3 at present. The company is slated to release third-quarter 2026 results on Nov. 4.

Acadia Healthcare’s earnings surpassed the Zacks Consensus Estimate in each of the trailing four quarters, the average surprise being 47%.

Agios Pharmaceuticals, Inc. (AGIO - Free Report) has an Earnings ESP of +9.37% and a Zacks Rank of 3 at present. The company is scheduled to release third-quarter 2026 results on Nov. 5.

Agios Pharmaceuticals’ earnings surpassed the Zacks Consensus Estimate in each of the preceding four quarters, the average surprise being 7.4%.

Becton, Dickinson and Company (BDX - Free Report) has an Earnings ESP of +0.21% and a Zacks Rank of 2 at present. The company is slated to release fourth-quarter fiscal 2026 (ended September 2026) results on Nov. 5.

Becton’s earnings surpassed the Zacks Consensus Estimate in each of the trailing four quarters, the average surprise being 2.9%.

, /PRNewswire/ -- Danaher Corporation (NYSE: DHR) today announced results for the third quarter 2026.  All results in this release reflect only continuing operations and period-to-period comparisons are year-over-year unless otherwise noted.

Key Third Quarter 2026 Results

Net earnings were $1.2 billion, or $1.71 per diluted common share, up 34.5% year-over-year.
Non-GAAP adjusted diluted net earnings per common share grew 11.5% to $2.11.
Revenues increased 8.5% year-over-year to $6.6 billion.
Non-GAAP core revenue excluding respiratory revenue increased 5.5% year-over-year and non-GAAP core revenue increased 3.0% year-over-year.
Operating cash flow was $1.9 billion and non-GAAP free cash flow was $1.6 billion.

Julie Sawyer Montgomery, President and Chief Executive Officer, stated, "We delivered better-than-expected third quarter revenue, earnings and cash flow, and are encouraged by the improving trends we saw across our end markets.  The continued acceleration in core revenue growth excluding respiratory revenue, together with DBS-driven execution drove double-digit adjusted EPS growth and underscored our ability to convert improving demand into strong financial performance."

Ms. Sawyer Montgomery continued, "Danaher has built a strong foundation, and the time I've spent with our teams and customers during my transition into the CEO role has only reinforced my conviction in the opportunities ahead.  Looking forward, the opportunity for Danaher is clear: to become the defining leader in Life Sciences and Diagnostics–a company that unambiguously gains share, delivers sustainable profitable growth, and helps our customers improve outcomes for patients around the world."

Fourth Quarter and Full Year 2026 Outlook

Danaher Corporation (the "Company") does not reconcile non-GAAP forecasted core sales growth, adjusted operating profit margin and adjusted diluted net earnings per common share to their respective, comparable measure prepared in accordance with U.S. generally accepted accounting principles (GAAP) because (except for estimated amortization of acquisition-related intangible assets of $0.5 billion for the fourth quarter and $1.9 billion for the year ending December 31, 2026 and the estimated impact of foreign currency on sales, which is estimated to be flat in the fourth quarter and increase sales by 1.0% in the full year, assuming the currency exchange rates in effect as of September 25, 2026) the additional elements that would be reflected in any such GAAP measures (such as the impact of currency exchange rates on profitability, future acquisitions, divested product lines, discrete tax adjustments, impairments, gains and losses on investments and the outcome of legal proceedings) are difficult to predict and estimate and are often dependent on future events that may be uncertain or outside of our control.  The impact of these additional elements could be material to our results computed in accordance with GAAP.

For the fourth quarter 2026, the Company anticipates that non-GAAP core revenue excluding respiratory revenue will increase in the 4.0% to 5.0% range year-over-year.  We expect respiratory revenue to be an approximately 150 basis point headwind, resulting in core revenue growth of approximately 3.0%.

For full year 2026, the Company is increasing its full year adjusted diluted net earnings per common share guidance to a range of $8.57 to $8.62 versus previous guidance of $8.45 to $8.60.

Conference Call and Webcast Information

Danaher will discuss its third quarter results and financial guidance for the fourth quarter and full year 2026, including as applicable key assumptions with respect thereto, during its investor conference call today starting at 8:00 a.m. ET.  The call and an accompanying slide presentation will be webcast on the "Investors" section of Danaher's website, www.danaher.com, under the subheading "Events & Presentations."  A replay of the webcast will be available in the same section of Danaher's website shortly after the conclusion of the presentation and will remain available until the next quarterly earnings call.

The conference call can be accessed by dialing 800-267-6316, within the U.S. or +1 203-518-9783 outside the U.S. a few minutes before 8:00 a.m. ET and notifying the operator that you are dialing in for Danaher's earnings conference call (Conference ID: DHRQ326).  A replay of the conference call will be available shortly after the conclusion of the call and until November 4, 2026.  You can access the replay dial-in information on the "Investors" section of Danaher's website under the subheading "Events & Presentations."

ABOUT DANAHER

Danaher is a leading global life sciences, diagnostics and biotechnology innovator committed to advancing the power of science and technology to improve human health. Through a connected ecosystem of industry-leading businesses, the Company works closely with customers to solve many of their most complex scientific challenges by accelerating discovery, development and the delivery of life-changing therapies. Powered by the Danaher Business System and 60,000 associates worldwide, the Company strives for continuous improvement, operational excellence and Innovation at the Speed of Life. Explore more at www.danaher.com.

NON-GAAP MEASURES AND SUPPLEMENTAL MATERIALS

In addition to the financial measures prepared in accordance with GAAP, this earnings release also contains non-GAAP financial measures.  Calculations of these measures, explanations of what these measures represent and the reasons why we believe these measures provide useful information to investors, a reconciliation of these measures to the most directly comparable GAAP measures, where applicable, and other information relating to these non-GAAP measures are included in the supplemental reconciliation schedule attached.

In addition, this earnings release, the slide presentation accompanying the related earnings call, non-GAAP reconciliations and a note containing details of historical and anticipated, future financial performance have been posted to the "Investors" section of Danaher's website (www.danaher.com).

FORWARD-LOOKING STATEMENTS AND OTHER INFORMATION

Statements in this release that are not strictly historical, including the statements regarding the Company's anticipated financial results for the fourth quarter and full year 2026, the Company's expectations regarding business trends, opportunities, market share gains, sustainable profitable growth and improved patient outcomes and any other statements regarding events or developments that we believe or anticipate will or may occur in the future are "forward-looking" statements within the meaning of the federal securities laws.  There are a number of important factors that could cause actual results, developments and business decisions to differ materially from those suggested or indicated by such forward-looking statements and you should not place undue reliance on any such forward-looking statements.  These factors include, among other things: the impact of the tariffs and related actions implemented by the U.S. and other countries, the impact of our debt obligations (including debt we incurred to finance the acquisition of Masimo Corporation)  on our operations and liquidity, deterioration of or instability in the global economy, the markets we serve and the financial markets, uncertainties with respect to the development, deployment, and use of artificial intelligence in our business and products, the impact of global health crises, uncertainties relating to national laws or policies, including laws or policies to protect or promote domestic interests and/or address foreign competition, our ability to successfully identify and consummate appropriate acquisitions and strategic investments, our ability to integrate the businesses we acquire and achieve the anticipated growth, synergies and other benefits of such acquisitions, contingent liabilities and other risks relating to acquisitions, investments, strategic relationships and divestitures (in each case, including with respect to our acquisition of Masimo Corporation), including tax-related and other contingent liabilities relating to past and future IPOs, split-offs or spin-offs, contractions or growth rates and cyclicality of markets we serve, competition, our ability to develop and successfully market new products and technologies and expand into new markets, the potential for improper conduct by our employees, agents or business partners, our compliance with applicable laws and regulations (including rules relating to off-label marketing and other regulations relating to medical devices and the health care industry), the results of our clinical trials and perceptions thereof, our ability to effectively address cost reductions and other changes in the health care industry, security breaches or other disruptions of our information technology systems or violations of data privacy laws, risks relating to potential impairment of goodwill and other intangible assets, currency exchange rates, tax audits and changes in our tax rate and income tax liabilities, changes in tax laws applicable to multinational companies, litigation, regulatory proceedings and other contingent liabilities including intellectual property and environmental, health and safety matters, the rights of the United States government with respect to our production capacity in times of national emergency or with respect to intellectual property/production capacity developed using government funding, risks relating to product, service or software defects, product liability and recalls, risks relating to our manufacturing operations, the impact of climate change, legal or regulatory measures to address climate change and other sustainability topics and our ability to address regulatory requirements or stakeholder expectations relating to climate change and other sustainability topics, risks relating to fluctuations in the cost and availability of the supplies we use (including commodities) and labor we need for our operations, our relationships with and the performance of our channel partners, uncertainties relating to collaboration arrangements with third-parties, the impact of deregulation on demand for our products and services, labor matters and our ability to recruit, retain and motivate talented employees, U.S. and non-U.S. economic, political, geopolitical, legal, compliance, social and business factors (including the impact of elections, regulatory and policy changes or uncertainty, government shutdowns and  military conflicts such as the conflict in the Middle East), disruptions and other impacts relating to man-made and natural disasters, inflation and the impact of our By-law exclusive forum provisions.  Additional information regarding the factors that may cause actual results to differ materially from these forward-looking statements is available in our SEC filings, including our 2025 Annual Report on Form 10-K and Quarterly Report on Form 10-Q for the third quarter of 2026.  These forward-looking statements speak only as of the date of this release and except to the extent required by applicable law, the Company does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events and developments or otherwise.

This press release may include descriptions of certain products and/or devices that have applications submitted and pending for certain regulatory approvals, or are available only in certain markets.

DANAHER CORPORATION AND SUBSIDIARIES

CONSOLIDATED CONDENSED STATEMENTS OF EARNINGS

($ and shares in millions, except per share amounts)

(unaudited)

Three-Month Period Ended

Nine-Month Period Ended

September 25, 2026

September 26, 2025

September 25, 2026

September 26, 2025

Sales

$           6,554

$           6,053

$          18,770

$          17,730

Cost of sales

(2,717)

(2,530)

(7,731)

(7,173)

Gross profit

3,837

3,523

11,039

10,557

Operating costs:

Selling, general and administrative
expenses

(2,159)

(1,991)

(6,091)

(6,209)

Research and development
expenses

(433)

(378)

(1,232)

(1,160)

Operating profit

1,245

1,154

3,716

3,188

Nonoperating income (expense):

Other income (expense), net

(9)

(14)

(85)

(135)

Interest expense

(135)

(67)

(305)

(210)

Interest income

31

3

119

17

Earnings before income taxes

1,132

1,076

3,445

2,860

Income taxes

75

(168)

(339)

(443)

Net earnings from continuing operations

1,207

908

3,106

2,417

Earnings from discontinued operations,
net of income taxes

28

—

28

—

Net earnings

$           1,235

$              908

$           3,134

$           2,417

Net earnings per common share from
continuing operations:

Basic

$             1.71

$             1.28

$             4.40

(a)

$             3.38

Diluted

$             1.71

$             1.27

$             4.38

(a)

$             3.37

Net earnings per common share from
discontinued operations:

Basic

$             0.04

$                —

$             0.04

$                —

Diluted

$             0.04

$                —

$             0.04

$                —

Net earnings per common share:

Basic

$             1.75

$             1.28

$             4.44

(a)

$             3.38

(a)

Diluted

$             1.75

$             1.27

$             4.42

(a)

$             3.37

(a)

Average common stock and common
equivalent shares outstanding:

Basic

703.8

710.7

705.7

714.5

Diluted

706.8

713.7

708.5

717.9

(a)

Net earnings per common share amounts for the relevant three-month periods do not add to the nine-month period amount due to rounding.

This information is presented for reference only.  A complete copy of Danaher's Form 10-Q financial statements is available on the Company's website (www.danaher.com).

DANAHER CORPORATION

RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES

Diluted Net Earnings Per Common Share from Continuing Operations and Adjusted Diluted Net Earnings Per
Common Share from Continuing Operations

Three-Month Period Ended

Nine-Month Period Ended

September 25,
2026

September 26,
2025

September 25,
2026

September 26,
2025

Diluted Net Earnings Per Common Share From
Continuing Operations (GAAP)

$           1.71

$           1.27

$           4.38

$           3.37

Amortization of acquisition-related intangible
assets A

0.73

0.61

1.99

1.77

Fair value net (gains) losses on investments B

0.02

0.02

0.14

0.21

Acquisition-related items C

0.12

—

0.29

—

Impairments D

0.07

0.14

0.07

0.76

Special equity awards compensation expense E

0.02

—

0.02

—

Settlement of acquisition-related contingency F

(0.01)

—

(0.01)

—

Gain on a product line disposition G

—

—

—

(0.01)

Tax effect of the above adjustments H

(0.17)

(0.15)

(0.43)

(0.54)

Discrete tax adjustments I

(0.37)

—

(0.34)

0.02

Rounding

(0.01)

—

—

(0.01)

Adjusted Diluted Net Earnings Per Common
Share From Continuing Operations (Non-GAAP)

$           2.11

$           1.89

$           6.11

$           5.57

Notes to Reconciliation of GAAP to Non-GAAP Financial Measures

A 

Amortization of acquisition-related intangible assets in the following historical periods ($ in millions) (only the pretax amounts set forth below are reflected in the amortization line item above):

Three-Month Period Ended

Nine-Month Period Ended

September 25,
2026

September 26,
2025

September 25,
2026

September 26,
2025

Pretax

$            513

$            433

$          1,410

$          1,269

After-tax

426

359

1,170

1,053

B

Net (gains) losses on the Company's equity and limited partnership investments recorded in the following historical periods ($ in millions) (only the pretax amounts set forth below are reflected in the fair value net (gains) losses on investments line above):

Three-Month Period Ended

Nine-Month Period Ended

September 25,
2026

September 26,
2025

September 25,
2026

September 26,
2025

Pretax

$             13

$             15

$             97

$            149

After-tax

10

12

74

113

C

Fair value adjustments to inventory in the three and nine-month periods ended September 25, 2026 ($84 million and $130 million pretax as reported in this line item, $67 million and $103 million after-tax, respectively), transaction costs deemed significant and pre-acquisition share-based and change-in-control payments in each case related to the acquisition of Masimo Corporation in the nine-month period ended September 25, 2026 ($79 million pretax as reported in this line item, $74 million after-tax).  The Company deems acquisition-related transaction costs incurred in a given period to be significant (generally relating to the Company's larger acquisitions) if it determines that such costs exceed the range of acquisition-related transaction costs typical for Danaher in a given period.

D

Impairment charges related to a facility in the Biotechnology segment recorded in both the three and nine-month periods ended September 25, 2026 ($52 million pretax as reported in this line item, $39 million after-tax), technology and other intangible assets in the Biotechnology segment recorded in both the three and nine-month periods ended September 26, 2025 ($86 million pretax as reported in this line item, $58 million after-tax), a trade name in the Diagnostics segment recorded in both the three and nine-month periods ended September 26, 2025 ($15 million pretax as reported in this line item, $12 million after-tax), a trade name in the Life Sciences segment recorded in the nine-month period ended September 26, 2025 ($432 million pretax as reported in this line item, $328 million after-tax) and a facility in the Biotechnology segment recorded in the nine-month period ended September 26, 2025 ($15 million pretax as reported in this line item, $11 million after-tax).

E

Compensation expense in the three and nine-month periods ended September 25, 2026 related to special long-term growth equity awards granted to the Company's founders, certain executive officers and other key leaders in the third quarter of 2026 ("special equity awards") ($14 million pretax as reported in this line item, $14 million after-tax).  These awards have vesting terms and amounts that differ from the Company's typical annual equity grants.

F

Settlement of an acquisition-related contingency in the Life Sciences segment in the three and nine-month periods ended September 25, 2026 ($8 million pretax as reported in this line item, $6 million after-tax).

G

Gain on a product line disposition in the nine-month period ended September 26, 2025 ($9 million pretax as reported in this line item, $7 million after-tax).

H

This line item reflects the aggregate tax effect of all nontax adjustments reflected in the preceding line items of the table.  In addition, the footnotes above indicate the after-tax amount of each individual adjustment item.  Danaher estimates the tax effect of each adjustment item by applying Danaher's overall estimated effective tax rate to the pretax amount, unless the nature of the item and/or the tax jurisdiction in which the item has been recorded requires application of a specific tax rate or tax treatment, in which case the tax effect of such item is estimated by applying such specific tax rate or tax treatment.

I

Discrete tax adjustments and other tax-related adjustments for the three-month period ended September 25, 2026, include the impact of net discrete tax benefits of $263 million related primarily to the release of reserves for uncertain tax positions resulting from audit settlements.  Discrete tax adjustments and other tax-related adjustments for the nine-month period ended September 25, 2026, include the impact of net discrete tax benefits of $242 million related primarily to the release of reserves for uncertain tax positions resulting from audit settlements and the expiration of statutes of limitations during the nine-month period, partially offset by changes in estimates associated with prior period uncertain tax positions.  There were no net discrete tax adjustments for the three-month period ended September 26, 2025, as a valuation allowance recorded on certain foreign operating losses was offset by benefits from the remeasurement of deferred taxes in a jurisdiction which enacted a tax rate change.  Discrete tax adjustments and other tax-related adjustments for the nine-month period ended September 26, 2025, include the impact of net discrete tax charges of $12 million related primarily to a valuation allowance recorded on certain foreign operating losses and changes in uncertain tax positions, partially offset by the remeasurement of deferred taxes in a jurisdiction which enacted a tax rate change and the release of reserves for uncertain tax positions due to the expiration of statutes of limitations.

Sales Growth by Segment, Core Sales Growth (Decline) by Segment and Core Sales Growth Excluding
Respiratory Testing

% Change Three-Month Period Ended September 25, 2026 vs. Comparable 2025
Period

Segments

Total Company

Biotechnology

Life Sciences

Diagnostics

Total sales growth (GAAP)

8.5 %

0.5 %

4.0 %

17.0 %

Impact of:

Acquisitions/divestitures

(6.5) %

— %

— %

(16.5) %

Currency exchange rates

— %

0.5 %

0.5 %

— %

Tariff refunds to customers

1.0 %

4.0 %

— %

— %

Core sales growth (non-GAAP)

3.0 %

5.0 %

4.5 %

0.5 %

Impact of respiratory testing

2.5 %

6.5 %

Core sales growth excluding respiratory
testing (non-GAAP)

5.5 %

7.0 %

% Change Nine-Month Period Ended September 25, 2026 vs. Comparable 2025 Period

Segments

Total Company

Biotechnology

Life Sciences

Diagnostics

Total sales growth (GAAP)

6.0 %

5.0 %

4.5 %

7.5 %

Impact of:

Acquisitions/divestitures

(3.0) %

— %

— %

(7.0) %

Currency exchange rates

(1.5) %

(1.5) %

(1.0) %

(1.0) %

Tariff refunds to customers

0.5 %

1.0 %

— %

— %

Core sales growth (decline) (non-GAAP)

2.0 %

4.5 %

3.5 %

(0.5) %

Impact of respiratory testing

2.5 %

5.5 %

Core sales growth excluding respiratory
testing (non-GAAP)

4.5 %

5.0 %

Note: Beginning with the Company's Quarterly Report on Form 10-Q for the third quarter of 2026, the Company is excluding from core sales growth and core sales excluding respiratory testing the impact, if any, of tariff refunds received by the Company (related to tariff payments made in prior periods) that are returned or to be returned to customers ("tariff refunds to customers").

Non-GAAP Forward-Looking Information

% Change Three-
Month Period Ending
December 31, 2026
vs. Comparable 2025
Period

% Change Year
Ending December 31,
2026 vs. Comparable
2025 Period

Core sales growth (non-GAAP)

Biotechnology

+Mid-single digit

+Mid-single digit

Life Sciences

+4.0% - +5.0%

+3.0% - +4.0%

Diagnostics

+Up slightly

~Flat

Total Company

~+3.0%

~+2.5%

Impact of respiratory testing

~+150 basis points

+Low-single digit

Core sales growth excluding respiratory testing (non-GAAP)

+4.0% - +5.0%

+Mid-single digit

Note: For the impact of respiratory testing, a positive amount represents a year-over-year headwind to core sales growth, and a negative amount represents a year-over-year tailwind to core sales growth.

Three-Month Period
Ending

December 31, 2026

Year Ending

December 31, 2026

Adjusted operating profit margin (non-GAAP)

 ~29.5  %

Adjusted diluted net earnings per common share from continuing operations
(non-GAAP)

$8.57 - $8.62

Other Forward-Looking Information

Three-Month Period
Ending

December 31, 2026

Year Ending

December 31, 2026

Impact of currency exchange rates on sales J

~Flat

~+1.0%

Amortization of acquisition-related intangible assets ($ in millions)

~$(500)

~$(1,900)

Corporate expense K ($ in millions)

~$(90)

~$(355)

Interest expense, net L ($ in millions)

~$(120)

~$(305)

Effective tax rate

 ~17.0  %

 ~17.0  %

Average adjusted diluted shares (in millions)

~707

~708

J

Impact of currency exchange rates on sales for the fourth quarter and full year 2026 assumes the currency exchange rates in effect as of September 25, 2026.

K

Corporate expense represents the operating profit (GAAP) for the Company's Other segment, which consists of unallocated corporate costs and other costs not considered part of management's evaluation of reportable segment operating performance, less approximately $200 million in both periods of stock-based compensation expense associated with the special equity awards, which is inclusive in both periods of a $185 million charge related to certain of the special equity awards that have been canceled.

L

Interest expense, net is defined as interest expense net of interest income.  This line item is an assumption rather than a forecast.  The estimated interest expense, net is calculated assuming the currency exchange rates in effect as of September 25, 2026 are to prevail throughout the remainder of the period indicated and no change in the amount of commercial paper outstanding.

Historical Sales (Decline) Growth, Core Sales Growth and Core Sales Growth Excluding Respiratory Testing

% Change Three-Month Period Ended vs. Comparable 2024
Period

% Change
Year Ended
December 31,
2025 vs.
Comparable
2024 Period

% Change Three-Month Period
Ended vs. Comparable 2025
Period

March 28, 2025

June 27, 2025

September 26,
2025

December 31,
2025

March 27, 2026

June 26, 2026

Total sales (decline)
growth (GAAP)

(1.0) %

3.5 %

4.5 %

4.5 %

3.0 %

3.5 %

5.5 %

Impact of:

Acquisitions
/divestitures

(0.5) %

— %

— %

0.5 %

— %

— %

(1.5) %

Currency
exchange rates

1.5 %

(2.0) %

(1.5) %

(2.5) %

(1.0) %

(3.0) %

(1.0) %

Core sales growth
(non-GAAP)

— %

1.5 %

3.0 %

2.5 %

2.0 %

0.5 %

3.0 %

Impact of
respiratory testing

1.0 %

0.5 %

(0.5) %

1.5 %

0.5 %

2.5 %

1.5 %

Core sales growth
excluding
respiratory testing
(non-GAAP)

1.0 %

2.0 %

2.5 %

4.0 %

2.5 %

3.0 %

4.5 %

Note: For the impact of respiratory testing, a positive amount represents a year-over-year headwind to core sales growth, and a negative amount represents a year-over-year tailwind to core sales growth.

Historical and Forward-Looking Respiratory Testing Sales

($ in millions)

 Three-Month Period Ended

Year
Ended
December
31, 2025 M

Three-Month Period Ended

Three-
Month
Period
Ending
December
31, 2026

Year
Ending
December
31, 2026

March 28,
2025

June 27,
2025

September 26,
2025

December 31,
2025

March 27,
2026

June 26,
2026

September 25,
2026

Respiratory
testing
sales N

~$650

~$300

~$500

~$500

~$1,900

~$500

~$250

~$350

~$400

~$1,500

M

Respiratory testing sales amounts for the relevant three-month periods may not add to the year-to-date period amount due to rounding.

N

Actual respiratory testing sales are rounded to the nearest $50 million.

Cash Flow from Continuing Operations, Free Cash Flow from Continuing Operations and Related Measures

($ in millions)

Three-Month Period Ended

Year-over-
Year Change

Nine-Month Period Ended

Year-over-
Year Change

September 25,
2026

September 26,
2025

September 25,
2026

September 26,
2025

Total Cash Flow from Continuing
Operations:

Net cash provided by operating
activities from continuing operations
(GAAP)

$       1,886

$       1,662

$        4,742

$       4,299

Total cash used in investing
activities for continuing operations
(GAAP)

$        (300)

$         (312)

$     (10,696)

$        (812)

Total cash (used in) provided by
financing activities for continuing
operations (GAAP)

$        (262)

$      (2,781)

$        7,057

$      (4,283)

Free Cash Flow from Continuing
Operations:

Net cash provided by operating
activities from continuing operations
(GAAP)

$       1,886

$       1,662

 ~ 13.5  %

$       4,742

$       4,299

 ~ 10.5  %

Less: payments for additions to
property, plant & equipment (capital
expenditures) (GAAP)

(255)

(292)

(761)

(785)

Plus: proceeds from sales of
property, plant & equipment (capital
disposals) (GAAP)

1

—

1

10

Free cash flow from continuing
operations (non-GAAP)

$       1,632

$       1,370

 ~ 19.0  %

$       3,982

$       3,524

 ~ 13.0  %

Operating Cash Flow from
Continuing Operations to Net
Earnings from Continuing
Operations Conversion Ratio:

Net cash provided by operating
activities from continuing operations
(GAAP)

$       1,886

$       1,662

$       4,742

$       4,299

Net earnings from continuing
operations (GAAP)

1,207

908

3,106

2,417

Operating cash flow from continuing
operations to net earnings from
continuing operations conversion
ratio (GAAP)

1.56

1.83

1.53

1.78

Free Cash Flow from Continuing
Operations to Net Earnings from
Continuing Operations
Conversion Ratio:

Free cash flow from continuing
operations from above (non-GAAP)

$       1,632

$       1,370

$       3,982

$       3,524

Net earnings from continuing
operations (GAAP)

1,207

908

3,106

2,417

Free cash flow from continuing
operations to net earnings from
continuing operations conversion
ratio (non-GAAP)

1.35

1.51

1.28

1.46

We define free cash flow as operating cash flows, less payments for additions to property, plant and equipment ("capital expenditures") plus the proceeds from sales of plant, property and equipment ("capital disposals"). 

Statement Regarding Non-GAAP Measures

Each of the non-GAAP measures set forth above should be considered in addition to, and not as a replacement for or superior to, the comparable GAAP measure, and may not be comparable to similarly titled measures reported by other companies.  Management believes that these measures provide useful information to investors by offering additional ways of viewing Danaher Corporation's ("Danaher" or the "Company") results that, when reconciled to the corresponding GAAP measure, help our investors:

with respect to the profitability-related non-GAAP measures, understand the long-term profitability trends of our business and compare our profitability to prior and future periods and to our peers;
with respect to the non-GAAP measures related to core sales, identify underlying growth trends in our business and compare our sales performance with prior and future periods and to our peers; and
with respect to free cash flow (the "FCF Measure"), understand Danaher's ability to generate cash without external financings, strengthen its balance sheet, invest in its business and grow its business through acquisitions and other strategic opportunities (although a limitation of free cash flow is that it does not take into account the Company's debt service requirements and other non-discretionary expenditures, and as a result the entire free cash flow amount is not necessarily available for discretionary expenditures).

Management uses the non-GAAP measures referenced above to measure the Company's operating and financial performance, and uses core sales and non-GAAP measures similar to Adjusted Diluted Net Earnings Per Common Share From Continuing Operations, Adjusted Operating Profit and the FCF Measure in the Company's executive compensation program.

The items excluded from the non-GAAP measures set forth above have been excluded for the following reasons:

With respect to the profitability-related non-GAAP measures:
Amortization of Intangible Assets:  We exclude the amortization of acquisition-related intangible assets because the amount and timing of such charges are significantly impacted by the timing, size, number and nature of the acquisitions we consummate.  While we have a history of significant acquisition activity we do not acquire businesses on a predictable cycle, and the amount of an acquisition's purchase price allocated to intangible assets and the related amortization term are unique to each acquisition and can vary significantly from acquisition to acquisition.  Exclusion of this amortization expense facilitates more consistent comparisons of operating results over time between our newly acquired and long-held businesses, and with both acquisitive and non-acquisitive peer companies.  We believe however that it is important for investors to understand that such intangible assets contribute to sales generation and that intangible asset amortization related to past acquisitions will recur in future periods until such intangible assets have been fully amortized.
Restructuring Charges:  We exclude costs incurred pursuant to discrete restructuring plans that are fundamentally different (in terms of the size, strategic nature and planning requirements, as well as the inconsistent frequency, of such plans) from the ongoing productivity improvements that result from application of the Danaher Business System.  Because these restructuring plans are incremental to the core activities that arise in the ordinary course of our business and we believe are not indicative of Danaher's ongoing operating costs in a given period, we exclude these costs to facilitate a more consistent comparison of operating results over time.
Other Adjustments:  With respect to the other items excluded from the profitability-related non-GAAP measures, we exclude these items because they are of a nature and/or size that occur with inconsistent frequency, occur for reasons that may be unrelated to Danaher's commercial performance during the period and/or we believe that such items may obscure underlying business trends and make comparisons of long-term performance difficult. 

With respect to core sales and core sales excluding respiratory testing, (1) we exclude the impact of currency translation because it is not under management's control, is subject to volatility and can obscure underlying business trends, (2) we exclude the effect of acquisitions and divested product lines because the timing, size, number and nature of such transactions can vary significantly from period-to-period and between us and our peers, which we believe may obscure underlying business trends and make comparisons of long-term performance difficult and (3) beginning with the Company's Quarterly Report on Form 10-Q in the third quarter of 2026, we exclude tariff refunds to customers to help customers better understand underlying growth trends in the Company's business that otherwise may be obscured by such item.
With respect to core sales excluding respiratory testing, we exclude the impact of revenues related to the sale of respiratory testing products in the Company's molecular diagnostics business in the Diagnostics segment.  Demand for respiratory testing depends significantly on the severity levels of influenza and influenza-like illness in a given period, and these severity levels are not under management's control.  As a result, presenting core sales on a basis that combines respiratory testing revenue with other Diagnostics business revenues can obscure underlying growth trends within the Diagnostics businesses.  The Company believes that this measure complements core sales, enhances investors' understanding of the historical and anticipated performance of the Diagnostics businesses as a whole, including with respect to underlying growth trends and facilitates comparisons of period-to-period performance. 
With respect to the FCF Measure, we deduct payments for additions to property, plant and equipment (net of the proceeds from capital disposals) to demonstrate the amount of operating cash flow for the period that remains after accounting for the Company's capital expenditure requirements.

SOURCE Danaher Corporation

IFP Advisors Inc lifted its holdings in shares of Danaher Corporation (NYSE:DHR – Free Report) by 1,000.9% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 39,092 shares of the conglomerate’s stock after acquiring an additional 35,541 shares during the quarter. IFP Advisors Inc’s holdings in Danaher were worth $8,661,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Finer Wealth Management Inc. bought a new stake in Danaher during the 3rd quarter valued at approximately $616,000. Robertson Stephens Wealth Management LLC grew its holdings in shares of Danaher by 44.9% during the 3rd quarter. Robertson Stephens Wealth Management LLC now owns 20,199 shares of the conglomerate’s stock worth $4,475,000 after acquiring an additional 6,259 shares during the period. Frank Rimerman Advisors LLC grew its holdings in shares of Danaher by 181.9% during the 3rd quarter. Frank Rimerman Advisors LLC now owns 40,855 shares of the conglomerate’s stock worth $9,051,000 after acquiring an additional 26,363 shares during the period. Counterpoint Mutual Funds LLC bought a new position in shares of Danaher in the 3rd quarter worth approximately $661,000. Finally, Birch Hill Investment Advisors LLC raised its position in shares of Danaher by 9.6% in the 3rd quarter. Birch Hill Investment Advisors LLC now owns 40,549 shares of the conglomerate’s stock worth $8,984,000 after acquiring an additional 3,553 shares in the last quarter. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Danaher Stock Performance Shares of DHR opened at $228.87 on Monday. The company has a quick ratio of 1.25, a current ratio of 1.65 and a debt-to-equity ratio of 0.48. The business’s 50 day moving average price is $214.04 and its 200-day moving average price is $196.06. Danaher Corporation has a 52 week low of $160.93 and a 52 week high of $242.80. The stock has a market cap of $160.89 billion, a P/E ratio of 40.65, a P/E/G ratio of 2.88 and a beta of 0.76.

Danaher (NYSE:DHR – Get Free Report) last posted its quarterly earnings data on Monday, July 20th. The conglomerate reported $1.94 earnings per share for the quarter, beating analysts’ consensus estimates of $1.85 by $0.09. The company had revenue of $6.26 billion during the quarter, compared to analyst estimates of $6.12 billion. Danaher had a return on equity of 11.04% and a net margin of 15.95%. The firm’s revenue for the quarter was up 5.5% on a year-over-year basis. During the same quarter last year, the company earned $0.77 EPS. Equities research analysts anticipate that Danaher Corporation will post 8.53 earnings per share for the current fiscal year. Danaher Announces Dividend The business also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be paid a $0.40 dividend. This represents a $1.60 dividend on an annualized basis and a dividend yield of 0.7%. The ex-dividend date of this dividend is Wednesday, September 30th. Danaher’s dividend payout ratio is currently 28.42%.

Analysts Set New Price Targets A number of research analysts have recently commented on DHR shares. Morgan Stanley raised their target price on Danaher from $220.00 to $240.00 and gave the company an “overweight” rating in a research note on Monday, October 12th. Wall Street Zen cut Danaher from a “buy” rating to a “hold” rating in a research note on Sunday. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating and issued a $240.00 price objective on shares of Danaher in a report on Wednesday, July 22nd. Evercore reissued an “outperform” rating and set a $230.00 price objective on shares of Danaher in a research report on Monday, July 6th. Finally, UBS Group started coverage on Danaher in a research report on Wednesday, September 9th. They set a “buy” rating and a $250.00 price objective for the company. Two research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $235.41.

Read Our Latest Stock Analysis on DHR

About Danaher (Free Report)

Danaher Corporation (NYSE: DHR) is a global science and technology company that develops products, services and solutions for the life sciences, biotechnology and diagnostics markets. Its offerings help researchers, pharmaceutical and biotechnology companies, healthcare providers and other organizations conduct scientific research, develop and manufacture medicines, and diagnose disease.

The company operates through businesses that provide bioprocessing equipment and technologies, laboratory instruments, consumables, analytical tools and clinical diagnostic systems.

Read More Five stocks we like better than Danaher These 3 Green Stocks Have a Growth Story That Goes Far Beyond Washington Meta Claims Frontier-Class AI Status With New Muse Wonder Models Berkshire Just Backed This Little-Known Stock—Should You Chase It? Broadcom’s CEO Sees Years of AI Demand But Warns of a Bigger Threat to the Boom

Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.

Danaher Corporation (NYSE:DHR) will release earnings for its third quarter before the opening bell on Wednesday, Oct. 21.

Analysts expect the company to report quarterly earnings of $1.92 per share, up from $1.89 per share in the year-ago period. The consensus estimate for DHR’s quarterly revenue is $6.56 billion. It reported $6.05 billion last year, according to Benzinga Pro.

On Oct. 14, Danaher announced an AI collaboration with NVIDIA Corp (NASDAQ:NVDA) focused on autonomous science.

Danaher shares fell 1.1% to close at $229.04 on Friday.

Benzinga readers can access the latest analyst ratings on the Analyst Stock Ratings page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.

Let’s have a look at how Benzinga’s most-accurate analysts have rated the company in the recent period.

TD Cowen analyst Dan Brennan maintained a Buy rating and raised the price target from $236 to $255 on Oct. 13, 2026. This analyst has an accuracy rate of 73%. Barclays analyst Luke Sergott maintained an Overweight rating and boosted the price target from $230 to $255 on Oct. 7, 2026. This analyst has an accuracy rate of 69%. RBC Capital analyst Dan Leonard maintained an Outperform rating and raised the price target from $215 to $250 on Oct. 5, 2026. This analyst has an accuracy rate of 70%. Guggenheim analyst Subbu Nambi maintained the stock with a Buy rating and increased the price target from $200 to $250 on Oct. 1, 2026. This analyst has an accuracy rate of 78%. Wells Fargo analyst Brandon Couillard maintained an Equal-Weight rating and cut the price target from $212 to $195 on July 22, 2026. This analyst has an accuracy rate of 74%. Considering buying DHR stock? Here’s what analysts think:

Photo via Shutterstock

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

To add Benzinga News as your preferred source on Google, click here.

CWS Financial Advisors LLC bought a new stake in shares of Danaher Corporation (NYSE:DHR – Free Report) during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund bought 15,838 shares of the conglomerate’s stock, valued at approximately $3,509,000. Danaher makes up about 0.7% of CWS Financial Advisors LLC’s investment portfolio, making the stock its 23rd largest holding.

Several other hedge funds and other institutional investors also recently modified their holdings of the stock. BlackRock Inc. purchased a new stake in Danaher in the second quarter worth about $10,492,520,000. Wellington Management Group LLP boosted its position in Danaher by 10.4% during the 2nd quarter. Wellington Management Group LLP now owns 16,316,834 shares of the conglomerate’s stock valued at $3,108,031,000 after acquiring an additional 1,542,310 shares in the last quarter. Jupiter Topco LLC bought a new stake in Danaher during the 2nd quarter valued at approximately $1,456,317,000. Generation Investment Management LLP purchased a new position in shares of Danaher during the 2nd quarter worth approximately $1,287,949,000. Finally, Bank of America Corp DE purchased a new position in shares of Danaher during the 2nd quarter worth approximately $993,846,000. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Danaher Trading Down 1.1% Shares of NYSE DHR opened at $228.87 on Friday. Danaher Corporation has a 1 year low of $160.93 and a 1 year high of $242.80. The stock has a market cap of $160.89 billion, a P/E ratio of 40.65, a price-to-earnings-growth ratio of 2.88 and a beta of 0.76. The firm has a 50-day moving average of $214.04 and a 200 day moving average of $195.97. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.65 and a quick ratio of 1.25.

Danaher (NYSE:DHR – Get Free Report) last posted its quarterly earnings data on Monday, July 20th. The conglomerate reported $1.94 EPS for the quarter, topping the consensus estimate of $1.85 by $0.09. The business had revenue of $6.26 billion for the quarter, compared to analyst estimates of $6.12 billion. Danaher had a net margin of 15.95% and a return on equity of 11.04%. Danaher’s quarterly revenue was up 5.5% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.77 earnings per share. As a group, sell-side analysts expect that Danaher Corporation will post 8.53 EPS for the current fiscal year. Danaher Dividend Announcement The firm also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be paid a dividend of $0.40 per share. The ex-dividend date of this dividend is Wednesday, September 30th. This represents a $1.60 dividend on an annualized basis and a dividend yield of 0.7%. Danaher’s dividend payout ratio (DPR) is currently 28.42%.

Analyst Upgrades and Downgrades Several research analysts have recently issued reports on DHR shares. UBS Group started coverage on Danaher in a research report on Wednesday, September 9th. They issued a “buy” rating and a $250.00 target price for the company. Stifel Nicolaus lowered their target price on Danaher from $260.00 to $220.00 and set a “buy” rating for the company in a research note on Wednesday, July 22nd. Guggenheim lifted their price target on Danaher from $200.00 to $250.00 and gave the company a “buy” rating in a research report on Thursday, October 1st. Morgan Stanley upped their price target on Danaher from $220.00 to $240.00 and gave the stock an “overweight” rating in a research note on Monday, October 12th. Finally, Weiss Ratings raised Danaher from a “hold (c-)” rating to a “hold (c)” rating in a research note on Wednesday, September 16th. Two research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat.com, Danaher currently has an average rating of “Moderate Buy” and a consensus price target of $235.41.

Get Our Latest Analysis on Danaher

Danaher Company Profile (Free Report)

Danaher Corporation (NYSE: DHR) is a global science and technology company that develops products, services and solutions for the life sciences, biotechnology and diagnostics markets. Its offerings help researchers, pharmaceutical and biotechnology companies, healthcare providers and other organizations conduct scientific research, develop and manufacture medicines, and diagnose disease.

The company operates through businesses that provide bioprocessing equipment and technologies, laboratory instruments, consumables, analytical tools and clinical diagnostic systems.

Recommended Stories Five stocks we like better than Danaher Rocket Lab’s Neutron Delay Leaves Wall Street Bullish But Raises the Stakes for 2027 ManpowerGroup Stock Sinks on Q3 Results, But Fundamentals Stay Solid Does the AI Selloff Put Alphabet’s Breakout in Doubt? Bank Earnings Are Mixed—These 2 ETFs Offer Very Different Paths to a Recovery Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Corporation (NYSE:DHR – Free Report).

Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.

Birch Hill Investment Advisors LLC boosted its stake in shares of Danaher Corporation (NYSE:DHR – Free Report) by 9.6% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 40,549 shares of the conglomerate’s stock after acquiring an additional 3,553 shares during the quarter. Birch Hill Investment Advisors LLC’s holdings in Danaher were worth $8,984,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in the company. BlackRock Inc. bought a new position in shares of Danaher in the 2nd quarter valued at about $10,492,520,000. Wellington Management Group LLP increased its stake in shares of Danaher by 10.4% in the 2nd quarter. Wellington Management Group LLP now owns 16,316,834 shares of the conglomerate’s stock valued at $3,108,031,000 after acquiring an additional 1,542,310 shares during the last quarter. Jupiter Topco LLC acquired a new stake in Danaher in the second quarter worth $1,456,317,000. Generation Investment Management LLP bought a new position in shares of Danaher during the second quarter worth $1,287,949,000. Finally, Bank of America Corp DE bought a new stake in shares of Danaher in the 2nd quarter valued at $993,846,000. Institutional investors and hedge funds own 79.05% of the company’s stock.

Analyst Ratings Changes A number of analysts recently issued reports on DHR shares. Wells Fargo & Company lowered their target price on Danaher from $212.00 to $195.00 and set an “equal weight” rating for the company in a research note on Wednesday, July 22nd. Royal Bank Of Canada upped their price target on Danaher from $215.00 to $250.00 and gave the stock an “outperform” rating in a research report on Monday, October 5th. Barclays increased their target price on shares of Danaher from $230.00 to $255.00 and gave the stock an “overweight” rating in a report on Wednesday, October 7th. Weiss Ratings raised Danaher from a “hold (c-)” rating to a “hold (c)” rating in a research report on Wednesday, September 16th. Finally, Morgan Stanley increased their price objective on Danaher from $220.00 to $240.00 and gave the company an “overweight” rating in a report on Monday, October 12th. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $235.41.

Check Out Our Latest Stock Analysis on Danaher Danaher Price Performance NYSE:DHR opened at $228.87 on Friday. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.25 and a current ratio of 1.65. Danaher Corporation has a 52 week low of $160.93 and a 52 week high of $242.80. The firm’s 50-day simple moving average is $214.04 and its 200 day simple moving average is $195.97. The firm has a market cap of $160.89 billion, a price-to-earnings ratio of 40.65, a P/E/G ratio of 2.88 and a beta of 0.76.

Danaher (NYSE:DHR – Get Free Report) last posted its quarterly earnings data on Monday, July 20th. The conglomerate reported $1.94 EPS for the quarter, topping analysts’ consensus estimates of $1.85 by $0.09. The firm had revenue of $6.26 billion for the quarter, compared to analyst estimates of $6.12 billion. Danaher had a return on equity of 11.04% and a net margin of 15.95%. The company’s revenue was up 5.5% on a year-over-year basis. During the same quarter last year, the company earned $0.77 EPS. As a group, sell-side analysts predict that Danaher Corporation will post 8.53 earnings per share for the current year.

Danaher Dividend Announcement The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be paid a $0.40 dividend. The ex-dividend date of this dividend is Wednesday, September 30th. This represents a $1.60 annualized dividend and a yield of 0.7%. Danaher’s dividend payout ratio (DPR) is 28.42%.

About Danaher (Free Report)

Danaher Corporation (NYSE: DHR) is a global science and technology company that develops products, services and solutions for the life sciences, biotechnology and diagnostics markets. Its offerings help researchers, pharmaceutical and biotechnology companies, healthcare providers and other organizations conduct scientific research, develop and manufacture medicines, and diagnose disease.

The company operates through businesses that provide bioprocessing equipment and technologies, laboratory instruments, consumables, analytical tools and clinical diagnostic systems.

Read More Five stocks we like better than Danaher Rocket Lab’s Neutron Delay Leaves Wall Street Bullish But Raises the Stakes for 2027 ManpowerGroup Stock Sinks on Q3 Results, But Fundamentals Stay Solid Does the AI Selloff Put Alphabet’s Breakout in Doubt? Bank Earnings Are Mixed—These 2 ETFs Offer Very Different Paths to a Recovery Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Corporation (NYSE:DHR – Free Report).

Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.

Baugh & Associates LLC bought a new position in shares of Danaher Corporation (NYSE:DHR – Free Report) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 72,668 shares of the conglomerate’s stock, valued at approximately $16,100,000. Danaher comprises about 5.5% of Baugh & Associates LLC’s portfolio, making the stock its 4th biggest holding.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Veery Capital LLC raised its position in Danaher by 3.1% in the third quarter. Veery Capital LLC now owns 1,581 shares of the conglomerate’s stock valued at $350,000 after purchasing an additional 48 shares during the period. Studio Investment Management LLC lifted its holdings in Danaher by 3.3% during the 2nd quarter. Studio Investment Management LLC now owns 1,581 shares of the conglomerate’s stock worth $302,000 after buying an additional 51 shares during the last quarter. JDH Wealth Management LLC raised its position in shares of Danaher by 4.5% during the 1st quarter. JDH Wealth Management LLC now owns 1,264 shares of the conglomerate’s stock worth $240,000 after acquiring an additional 55 shares in the last quarter. OLD Second National Bank of Aurora raised its position in shares of Danaher by 0.5% during the 1st quarter. OLD Second National Bank of Aurora now owns 12,114 shares of the conglomerate’s stock worth $2,297,000 after acquiring an additional 57 shares in the last quarter. Finally, Adelphi Trust Co lifted its stake in Danaher by 2.5% during the third quarter. Adelphi Trust Co now owns 2,365 shares of the conglomerate’s stock worth $524,000 after purchasing an additional 57 shares during the last quarter. Institutional investors and hedge funds own 79.05% of the company’s stock.

Wall Street Analyst Weigh In DHR has been the subject of several research analyst reports. Wall Street Zen upgraded shares of Danaher from a “hold” rating to a “buy” rating in a research note on Saturday, October 10th. Wells Fargo & Company reduced their price target on shares of Danaher from $212.00 to $195.00 and set an “equal weight” rating for the company in a research report on Wednesday, July 22nd. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating and set a $240.00 price target on shares of Danaher in a research note on Wednesday, July 22nd. TD Cowen raised their price objective on shares of Danaher from $236.00 to $255.00 and gave the stock a “buy” rating in a research report on Tuesday. Finally, Evercore reaffirmed an “outperform” rating and issued a $230.00 target price on shares of Danaher in a report on Monday, July 6th. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $235.41.

Read Our Latest Stock Analysis on Danaher Danaher Stock Down 1.1% Shares of NYSE DHR opened at $228.87 on Friday. The firm’s 50 day moving average price is $214.04 and its 200 day moving average price is $195.97. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.25 and a current ratio of 1.65. The firm has a market cap of $160.89 billion, a P/E ratio of 40.65, a price-to-earnings-growth ratio of 2.91 and a beta of 0.76. Danaher Corporation has a 1 year low of $160.93 and a 1 year high of $242.80.

Danaher (NYSE:DHR – Get Free Report) last issued its quarterly earnings results on Monday, July 20th. The conglomerate reported $1.94 earnings per share for the quarter, topping analysts’ consensus estimates of $1.85 by $0.09. Danaher had a return on equity of 11.04% and a net margin of 15.95%. The company had revenue of $6.26 billion for the quarter, compared to analyst estimates of $6.12 billion. During the same quarter in the prior year, the company posted $0.77 EPS. The business’s revenue for the quarter was up 5.5% compared to the same quarter last year. As a group, sell-side analysts anticipate that Danaher Corporation will post 8.53 earnings per share for the current year.

Danaher Announces Dividend The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be issued a dividend of $0.40 per share. This represents a $1.60 dividend on an annualized basis and a dividend yield of 0.7%. The ex-dividend date is Wednesday, September 30th. Danaher’s dividend payout ratio is presently 28.42%.

Danaher Company Profile (Free Report)

Danaher Corporation (NYSE: DHR) is a global science and technology company that develops and manufactures products, services and solutions for the life sciences, diagnostics and biotechnology industries. Its offerings help researchers, healthcare professionals and biopharmaceutical manufacturers discover, develop, produce and analyze medicines and other biological products.

The company operates through businesses that provide laboratory instruments, consumables, software and services, including technologies for cell analysis, genomics, protein research, bioprocessing and clinical diagnostics.

Read More Five stocks we like better than Danaher Bank of America Stock Sell-Off Looks Like a Buying Opportunity AST SpaceMobile Is Down 67%—Could SpaceX’s Mobile Push Deepen the Selloff? GlobalFoundries’ $21 Billion Deal Could Change the Economics of Chipmaking Fundamental and Technicals Signals Align for Costco: Is the Stock Finally Breaking Out? Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Corporation (NYSE:DHR – Free Report).

Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.

Beaumont Asset Management L.L.C. purchased a new stake in shares of Danaher Corporation (NYSE:DHR – Free Report) in the third quarter, according to its most recent disclosure with the SEC. The firm purchased 7,604 shares of the conglomerate’s stock, valued at approximately $1,685,000.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. BlackRock Inc. purchased a new stake in shares of Danaher in the 2nd quarter valued at approximately $10,492,520,000. Wellington Management Group LLP grew its position in Danaher by 10.4% during the 2nd quarter. Wellington Management Group LLP now owns 16,316,834 shares of the conglomerate’s stock worth $3,108,031,000 after purchasing an additional 1,542,310 shares in the last quarter. Jupiter Topco LLC purchased a new position in Danaher during the 2nd quarter worth approximately $1,456,317,000. Generation Investment Management LLP purchased a new position in Danaher during the 2nd quarter worth approximately $1,287,949,000. Finally, Bank of America Corp DE acquired a new stake in Danaher during the 2nd quarter valued at $993,846,000. 79.05% of the stock is owned by institutional investors.

Danaher Stock Performance Shares of NYSE DHR opened at $228.87 on Friday. The firm has a market capitalization of $160.89 billion, a price-to-earnings ratio of 40.65, a PEG ratio of 2.91 and a beta of 0.76. Danaher Corporation has a one year low of $160.93 and a one year high of $242.80. The business has a fifty day simple moving average of $214.04 and a 200 day simple moving average of $195.97. The company has a current ratio of 1.65, a quick ratio of 1.25 and a debt-to-equity ratio of 0.48.

Danaher (NYSE:DHR – Get Free Report) last posted its quarterly earnings results on Monday, July 20th. The conglomerate reported $1.94 earnings per share for the quarter, topping analysts’ consensus estimates of $1.85 by $0.09. The firm had revenue of $6.26 billion for the quarter, compared to the consensus estimate of $6.12 billion. Danaher had a net margin of 15.95% and a return on equity of 11.04%. The business’s revenue was up 5.5% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.77 earnings per share. Sell-side analysts expect that Danaher Corporation will post 8.53 EPS for the current year. Danaher Announces Dividend The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be issued a dividend of $0.40 per share. This represents a $1.60 dividend on an annualized basis and a dividend yield of 0.7%. The ex-dividend date of this dividend is Wednesday, September 30th. Danaher’s dividend payout ratio (DPR) is presently 28.42%.

Analysts Set New Price Targets DHR has been the subject of a number of research analyst reports. TD Cowen increased their target price on Danaher from $236.00 to $255.00 and gave the company a “buy” rating in a report on Tuesday. Evercore reaffirmed an “outperform” rating and issued a $230.00 target price on shares of Danaher in a research report on Monday, July 6th. Wall Street Zen upgraded Danaher from a “hold” rating to a “buy” rating in a report on Saturday, October 10th. The Goldman Sachs Group upped their price target on Danaher from $210.00 to $250.00 and gave the company a “buy” rating in a research report on Monday, September 21st. Finally, Morgan Stanley upped their price target on Danaher from $220.00 to $240.00 and gave the company an “overweight” rating in a research report on Monday. Two research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and four have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $235.41.

Get Our Latest Analysis on DHR

About Danaher (Free Report)

Danaher Corporation (NYSE: DHR) is a global science and technology company that develops and manufactures products, services and solutions for the life sciences, diagnostics and biotechnology industries. Its offerings help researchers, healthcare professionals and biopharmaceutical manufacturers discover, develop, produce and analyze medicines and other biological products.

The company operates through businesses that provide laboratory instruments, consumables, software and services, including technologies for cell analysis, genomics, protein research, bioprocessing and clinical diagnostics.

Recommended Stories Five stocks we like better than Danaher Bank of America Stock Sell-Off Looks Like a Buying Opportunity AST SpaceMobile Is Down 67%—Could SpaceX’s Mobile Push Deepen the Selloff? GlobalFoundries’ $21 Billion Deal Could Change the Economics of Chipmaking Fundamental and Technicals Signals Align for Costco: Is the Stock Finally Breaking Out?

Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.

C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors acquired a new position in shares of Danaher Corporation (NYSE:DHR – Free Report) in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 2,973 shares of the conglomerate’s stock, valued at approximately $659,000.

A number of other hedge funds have also bought and sold shares of the company. BlackRock Inc. acquired a new position in shares of Danaher in the 2nd quarter valued at about $10,492,520,000. Wellington Management Group LLP boosted its position in shares of Danaher by 10.4% during the 2nd quarter. Wellington Management Group LLP now owns 16,316,834 shares of the conglomerate’s stock valued at $3,108,031,000 after purchasing an additional 1,542,310 shares in the last quarter. Jupiter Topco LLC bought a new stake in shares of Danaher during the 2nd quarter valued at about $1,456,317,000. Generation Investment Management LLP bought a new stake in shares of Danaher during the 2nd quarter valued at about $1,287,949,000. Finally, Bank of America Corp DE acquired a new stake in Danaher during the second quarter worth approximately $993,846,000. Institutional investors own 79.05% of the company’s stock.

Analyst Upgrades and Downgrades DHR has been the subject of a number of research analyst reports. Weiss Ratings upgraded Danaher from a “hold (c-)” rating to a “hold (c)” rating in a report on Wednesday, September 16th. Guggenheim increased their price target on Danaher from $200.00 to $250.00 and gave the stock a “buy” rating in a report on Thursday, October 1st. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and set a $240.00 price objective on shares of Danaher in a research report on Wednesday, July 22nd. Stifel Nicolaus lowered their price objective on shares of Danaher from $260.00 to $220.00 and set a “buy” rating for the company in a research note on Wednesday, July 22nd. Finally, Royal Bank Of Canada boosted their target price on shares of Danaher from $215.00 to $250.00 and gave the company an “outperform” rating in a research report on Monday, October 5th. Two research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat.com, Danaher presently has an average rating of “Moderate Buy” and an average target price of $235.41.

Check Out Our Latest Stock Report on Danaher Danaher Price Performance DHR opened at $231.52 on Friday. Danaher Corporation has a fifty-two week low of $160.93 and a fifty-two week high of $242.80. The firm has a 50-day moving average of $213.55 and a 200 day moving average of $195.74. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.25 and a current ratio of 1.65. The firm has a market cap of $162.76 billion, a P/E ratio of 41.12, a PEG ratio of 2.82 and a beta of 0.76.

Danaher (NYSE:DHR – Get Free Report) last released its earnings results on Monday, July 20th. The conglomerate reported $1.94 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.85 by $0.09. Danaher had a return on equity of 11.04% and a net margin of 15.95%. The business had revenue of $6.26 billion during the quarter, compared to the consensus estimate of $6.12 billion. During the same period last year, the business posted $0.77 earnings per share. The business’s revenue for the quarter was up 5.5% on a year-over-year basis. On average, research analysts expect that Danaher Corporation will post 8.53 EPS for the current year.

Danaher Dividend Announcement The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be issued a $0.40 dividend. The ex-dividend date of this dividend is Wednesday, September 30th. This represents a $1.60 annualized dividend and a yield of 0.7%. Danaher’s dividend payout ratio (DPR) is 28.42%.

Key Stories Impacting Danaher Here are the key news stories impacting Danaher this week:

Positive Sentiment: Danaher and NVIDIA announced an AI collaboration to combine Danaher’s scientific instruments, laboratory workflows, automation technology and software with NVIDIA’s accelerated computing and AI capabilities. The partnership is intended to advance autonomous science and speed drug discovery and other laboratory research. Danaher Collaborates with NVIDIA to Advance Autonomous Science Positive Sentiment: Danaher is also preparing to launch its first AI-powered autonomous laboratory, targeted to operate at commercial scale in early 2027. The initiative could support longer-term growth in laboratory automation and strengthen the company’s position in AI-enabled life-science research. How to Invest in AI Drug Discovery Positive Sentiment: Multiple Zacks reports say Danaher has a favorable combination of earnings-estimate trends and Earnings ESP, suggesting potential for the company to exceed consensus estimates in its next quarterly report. Danaher has also recently demonstrated earnings momentum, with its latest reported quarter exceeding both EPS and revenue expectations. Will Danaher Beat Estimates Again in Its Next Earnings Report? Neutral Sentiment: Danaher is projected to announce earnings on Wednesday. Investors will be watching revenue growth, management’s outlook and whether diagnostics and life-sciences demand support the anticipated improvement in earnings. Danaher Projected to Announce Earnings Danaher Profile (Free Report)

Danaher Corporation (NYSE: DHR) is a global science and technology company that develops and manufactures products, services and solutions for the life sciences, diagnostics and biotechnology industries. Its offerings help researchers, healthcare professionals and biopharmaceutical manufacturers discover, develop, produce and analyze medicines and other biological products.

The company operates through businesses that provide laboratory instruments, consumables, software and services, including technologies for cell analysis, genomics, protein research, bioprocessing and clinical diagnostics.

Featured Stories Five stocks we like better than Danaher ASML Can’t Keep Up With AI Demand—Why That’s a Good Thing Enovix’s 100,000-Battery Drone Order Sets Up a Test of Its Production Plans AMD’s Support Could Help Fermi Stock Overcome Its Biggest Hurdle Beyond the GPU: Credo Paves the Next AI Data Superhighway

Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.

Charles Schwab Trust Co purchased a new stake in Danaher Corporation (NYSE:DHR – Free Report) during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 3,427 shares of the conglomerate’s stock, valued at approximately $759,000.

A number of other institutional investors also recently modified their holdings of the business. BlackRock Inc. acquired a new position in Danaher during the 2nd quarter worth approximately $10,492,520,000. Wellington Management Group LLP lifted its stake in Danaher by 10.4% in the 2nd quarter. Wellington Management Group LLP now owns 16,316,834 shares of the conglomerate’s stock valued at $3,108,031,000 after purchasing an additional 1,542,310 shares during the last quarter. Jupiter Topco LLC acquired a new stake in Danaher in the second quarter valued at approximately $1,456,317,000. Generation Investment Management LLP acquired a new stake in Danaher in the second quarter valued at approximately $1,287,949,000. Finally, Bank of America Corp DE acquired a new stake in Danaher in the second quarter valued at approximately $993,846,000. Institutional investors and hedge funds own 79.05% of the company’s stock.

Analysts Set New Price Targets A number of equities research analysts recently weighed in on DHR shares. Stifel Nicolaus reduced their price objective on Danaher from $260.00 to $220.00 and set a “buy” rating on the stock in a research report on Wednesday, July 22nd. Barclays increased their target price on Danaher from $230.00 to $255.00 and gave the company an “overweight” rating in a research report on Wednesday, October 7th. UBS Group initiated coverage on Danaher in a research report on Wednesday, September 9th. They issued a “buy” rating and a $250.00 target price for the company. TD Cowen lifted their price target on Danaher from $236.00 to $255.00 and gave the company a “buy” rating in a research note on Tuesday. Finally, Deutsche Bank Aktiengesellschaft restated a “buy” rating and set a $240.00 price target on shares of Danaher in a report on Wednesday, July 22nd. Two analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $235.41.

Check Out Our Latest Research Report on DHR Key Stories Impacting Danaher Here are the key news stories impacting Danaher this week:

Positive Sentiment: Danaher and NVIDIA announced an AI collaboration to combine Danaher’s scientific instruments, laboratory workflows, automation technology and software with NVIDIA’s accelerated computing and AI capabilities. The partnership is intended to advance autonomous science and speed drug discovery and other laboratory research. Danaher Collaborates with NVIDIA to Advance Autonomous Science Positive Sentiment: Danaher is also preparing to launch its first AI-powered autonomous laboratory, targeted to operate at commercial scale in early 2027. The initiative could support longer-term growth in laboratory automation and strengthen the company’s position in AI-enabled life-science research. How to Invest in AI Drug Discovery Positive Sentiment: Multiple Zacks reports say Danaher has a favorable combination of earnings-estimate trends and Earnings ESP, suggesting potential for the company to exceed consensus estimates in its next quarterly report. Danaher has also recently demonstrated earnings momentum, with its latest reported quarter exceeding both EPS and revenue expectations. Will Danaher Beat Estimates Again in Its Next Earnings Report? Neutral Sentiment: Danaher is projected to announce earnings on Wednesday. Investors will be watching revenue growth, management’s outlook and whether diagnostics and life-sciences demand support the anticipated improvement in earnings. Danaher Projected to Announce Earnings Danaher Price Performance Danaher stock opened at $231.52 on Friday. The stock’s 50 day moving average is $213.55 and its 200 day moving average is $195.74. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.65 and a quick ratio of 1.25. The firm has a market cap of $162.76 billion, a P/E ratio of 41.12, a P/E/G ratio of 2.82 and a beta of 0.76. Danaher Corporation has a one year low of $160.93 and a one year high of $242.80.

Danaher (NYSE:DHR – Get Free Report) last issued its quarterly earnings results on Monday, July 20th. The conglomerate reported $1.94 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.85 by $0.09. Danaher had a return on equity of 11.04% and a net margin of 15.95%. The firm had revenue of $6.26 billion for the quarter, compared to analyst estimates of $6.12 billion. During the same period in the previous year, the firm earned $0.77 earnings per share. The company’s revenue was up 5.5% compared to the same quarter last year. As a group, research analysts expect that Danaher Corporation will post 8.53 EPS for the current year.

Danaher Dividend Announcement The business also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be given a $0.40 dividend. This represents a $1.60 dividend on an annualized basis and a yield of 0.7%. The ex-dividend date of this dividend is Wednesday, September 30th. Danaher’s dividend payout ratio is presently 28.42%.

Danaher Company Profile (Free Report)

Danaher Corporation (NYSE: DHR) is a global science and technology company that develops and manufactures products, services and solutions for the life sciences, diagnostics and biotechnology industries. Its offerings help researchers, healthcare professionals and biopharmaceutical manufacturers discover, develop, produce and analyze medicines and other biological products.

The company operates through businesses that provide laboratory instruments, consumables, software and services, including technologies for cell analysis, genomics, protein research, bioprocessing and clinical diagnostics.

Featured Articles Five stocks we like better than Danaher ASML Can’t Keep Up With AI Demand—Why That’s a Good Thing Enovix’s 100,000-Battery Drone Order Sets Up a Test of Its Production Plans AMD’s Support Could Help Fermi Stock Overcome Its Biggest Hurdle Beyond the GPU: Credo Paves the Next AI Data Superhighway Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Corporation (NYSE:DHR – Free Report).

Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.

Chiron Capital Management LLC trimmed its position in shares of Danaher Corporation (NYSE:DHR – Free Report) by 66.1% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,901 shares of the conglomerate’s stock after selling 3,700 shares during the period. Chiron Capital Management LLC’s holdings in Danaher were worth $421,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Veery Capital LLC boosted its position in Danaher by 3.1% in the 3rd quarter. Veery Capital LLC now owns 1,581 shares of the conglomerate’s stock valued at $350,000 after buying an additional 48 shares during the last quarter. Studio Investment Management LLC grew its stake in shares of Danaher by 3.3% during the second quarter. Studio Investment Management LLC now owns 1,581 shares of the conglomerate’s stock valued at $302,000 after acquiring an additional 51 shares in the last quarter. JDH Wealth Management LLC increased its position in shares of Danaher by 4.5% during the first quarter. JDH Wealth Management LLC now owns 1,264 shares of the conglomerate’s stock worth $240,000 after acquiring an additional 55 shares during the last quarter. OLD Second National Bank of Aurora increased its position in shares of Danaher by 0.5% during the first quarter. OLD Second National Bank of Aurora now owns 12,114 shares of the conglomerate’s stock worth $2,297,000 after acquiring an additional 57 shares during the last quarter. Finally, Adelphi Trust Co increased its position in shares of Danaher by 2.5% during the third quarter. Adelphi Trust Co now owns 2,365 shares of the conglomerate’s stock worth $524,000 after acquiring an additional 57 shares during the last quarter. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Danaher Stock Performance Shares of NYSE DHR opened at $231.52 on Friday. The company has a quick ratio of 1.25, a current ratio of 1.65 and a debt-to-equity ratio of 0.48. The firm’s 50-day moving average price is $213.55 and its two-hundred day moving average price is $195.74. Danaher Corporation has a 52-week low of $160.93 and a 52-week high of $242.80. The stock has a market capitalization of $162.76 billion, a P/E ratio of 41.12, a P/E/G ratio of 2.82 and a beta of 0.76.

Danaher (NYSE:DHR – Get Free Report) last issued its earnings results on Monday, July 20th. The conglomerate reported $1.94 EPS for the quarter, beating analysts’ consensus estimates of $1.85 by $0.09. The company had revenue of $6.26 billion during the quarter, compared to the consensus estimate of $6.12 billion. Danaher had a return on equity of 11.04% and a net margin of 15.95%. Danaher’s quarterly revenue was up 5.5% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.77 earnings per share. As a group, sell-side analysts forecast that Danaher Corporation will post 8.53 earnings per share for the current year. Danaher Dividend Announcement The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be given a dividend of $0.40 per share. The ex-dividend date is Wednesday, September 30th. This represents a $1.60 dividend on an annualized basis and a yield of 0.7%. Danaher’s payout ratio is currently 28.42%.

Key Headlines Impacting Danaher Here are the key news stories impacting Danaher this week:

Positive Sentiment: Danaher and NVIDIA announced an AI collaboration to combine Danaher’s scientific instruments, laboratory workflows, automation technology and software with NVIDIA’s accelerated computing and AI capabilities. The partnership is intended to advance autonomous science and speed drug discovery and other laboratory research. Danaher Collaborates with NVIDIA to Advance Autonomous Science Positive Sentiment: Danaher is also preparing to launch its first AI-powered autonomous laboratory, targeted to operate at commercial scale in early 2027. The initiative could support longer-term growth in laboratory automation and strengthen the company’s position in AI-enabled life-science research. How to Invest in AI Drug Discovery Positive Sentiment: Multiple Zacks reports say Danaher has a favorable combination of earnings-estimate trends and Earnings ESP, suggesting potential for the company to exceed consensus estimates in its next quarterly report. Danaher has also recently demonstrated earnings momentum, with its latest reported quarter exceeding both EPS and revenue expectations. Will Danaher Beat Estimates Again in Its Next Earnings Report? Neutral Sentiment: Danaher is projected to announce earnings on Wednesday. Investors will be watching revenue growth, management’s outlook and whether diagnostics and life-sciences demand support the anticipated improvement in earnings. Danaher Projected to Announce Earnings Wall Street Analyst Weigh In DHR has been the subject of a number of analyst reports. Barclays increased their price target on Danaher from $230.00 to $255.00 and gave the company an “overweight” rating in a report on Wednesday, October 7th. TD Cowen lifted their price objective on Danaher from $236.00 to $255.00 and gave the stock a “buy” rating in a report on Tuesday. Wells Fargo & Company cut their target price on Danaher from $212.00 to $195.00 and set an “equal weight” rating on the stock in a research report on Wednesday, July 22nd. Wall Street Zen upgraded Danaher from a “hold” rating to a “buy” rating in a research note on Saturday, October 10th. Finally, Royal Bank Of Canada increased their target price on Danaher from $215.00 to $250.00 and gave the company an “outperform” rating in a research note on Monday, October 5th. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat.com, Danaher presently has a consensus rating of “Moderate Buy” and a consensus price target of $235.41.

Check Out Our Latest Analysis on Danaher

Danaher Profile (Free Report)

Danaher Corporation (NYSE: DHR) is a global science and technology company that develops and manufactures products, services and solutions for the life sciences, diagnostics and biotechnology industries. Its offerings help researchers, healthcare professionals and biopharmaceutical manufacturers discover, develop, produce and analyze medicines and other biological products.

The company operates through businesses that provide laboratory instruments, consumables, software and services, including technologies for cell analysis, genomics, protein research, bioprocessing and clinical diagnostics.

Read More Five stocks we like better than Danaher ASML Can’t Keep Up With AI Demand—Why That’s a Good Thing Enovix’s 100,000-Battery Drone Order Sets Up a Test of Its Production Plans AMD’s Support Could Help Fermi Stock Overcome Its Biggest Hurdle Beyond the GPU: Credo Paves the Next AI Data Superhighway

Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.

Key Takeaways Danaher is expected to report Q3 revenues of $26.3 billion, up 8.2% year over year.Biotechnology, Diagnostics and Life Sciences growth, plus Masimo, may boost quarterly sales.Rising input costs, product mix changes and currency headwinds may pressure Danaher's profits. Danaher Corporation (DHR - Free Report) is scheduled to release third-quarter 2026 results on Oct. 21, before market open.

The Zacks Consensus Estimate for revenues is pegged at $26.3 billion, which indicates an increase of 8.2% from the year-ago quarter’s figure. The consensus mark for earnings is pinned at $1.94 per share, which has remained steady in the past 30 days. The estimate indicates an increase of 1.6% from the figure reported in the year-ago quarter. The company’s bottom line surpassed the Zacks Consensus Estimate in each of the preceding four quarters, the average beat being 5.7%.

Let’s see how things have shaped up for Danaher this earnings season.

Key Factors and Estimates for Q3Strength in the bioprocessing business, driven by an increase in demand from large pharmaceutical and biopharma customers, is expected to have aided the Biotechnology segment. The segment’s performance is also likely to have benefited from solid demand for equipment and consumables. For the third quarter, the Zacks Consensus Estimate for the segment’s total sales is pegged at $1.87 billion, indicating a 3.9% rise from the year-ago reported number.

Stabilizing pricing and improving volumes, as procurement and reimbursement effects have begun to moderate, are expected to drive the Diagnostics segment’s results. For the third quarter, the Zacks Consensus Estimate for the segment’s total sales is pegged at $2.83 billion, indicating a 15% rise from the year-ago reported number.

Increase in demand across filtration, instruments and consumables businesses is likely to have boosted the performance of the Life Sciences segment in the quarter. For the third quarter, the Zacks Consensus Estimate for the segment’s total sales is pegged at $1.84 billion, indicating a 2.8% rise from the year-ago reported number.

Danaher acquired Masimo in June 2026, which expanded the Diagnostics segment by adding sensor technology and AI-enabled monitoring. This is expected to have augmented the company’s top line in the third quarter.

However, the escalating costs and operating expenses, due to increasing input costs and product mix changes, are likely to have weighed on DHR’s bottom line in the to-be-reported quarter.

The company has considerable exposure to overseas markets. Given its substantial international operations, foreign currency headwinds are likely to have marred its profitability.

Earnings WhispersOur proven model predicts an earnings beat for DHR this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat, which is not the case here, as elaborated below.

Earnings ESP: DHR has an Earnings ESP of +0.30% as the Most Accurate Estimate is pegged at $1.93 per share, which is higher than the Zacks Consensus Estimate of $1.92. You can uncover the best stocks before they’re reported with our Earnings ESP Filter.

Zacks Rank: DHR currently carries a Zacks Rank of 2. You can see the complete list of today’s Zacks #1 Rank stocks here.

Other Stocks to ConsiderHere are some other companies within the broader Medical sector, which according to our model, have the right combination of elements to beat on earnings in this reporting cycle.

Acadia Healthcare Company, Inc. (ACHC - Free Report) has an Earnings ESP of +4.84% and a Zacks Rank of 3 at present. The company is slated to release third-quarter 2025 results on Nov. 4.

Acadia Healthcare’s earnings surpassed the Zacks Consensus Estimate in each of the trailing four quarters, the average surprise being 47%.

Agios Pharmaceuticals, Inc. (AGIO - Free Report) has an Earnings ESP of +9.37% and a Zacks Rank of 3 at present. The company is scheduled to release third-quarter 2026 results on Nov. 5.

Agios Pharmaceuticals’ earnings surpassed the Zacks Consensus Estimate in each of the preceding four quarters, the average surprise being 7.4%.

CVS Health Corporation (CVS - Free Report) has an Earnings ESP of +0.79% and a Zacks Rank of 3 at present. The company is slated to release third-quarter 2026 results on Nov. 4.

CVS Health’s earnings surpassed the Zacks Consensus Estimate in each of the trailing four quarters, the average surprise being 20.5%.

Foster Group Inc. bought a new stake in shares of Danaher Corporation (NYSE:DHR – Free Report) in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund bought 3,232 shares of the conglomerate’s stock, valued at approximately $716,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of the stock. B. Riley Wealth Advisors Inc. bought a new position in Danaher in the third quarter valued at $3,054,000. Krilogy Financial LLC raised its position in Danaher by 104.2% during the third quarter. Krilogy Financial LLC now owns 23,336 shares of the conglomerate’s stock valued at $5,170,000 after purchasing an additional 11,906 shares in the last quarter. Mechanics Bank Trust Department raised its position in Danaher by 188.0% during the third quarter. Mechanics Bank Trust Department now owns 27,995 shares of the conglomerate’s stock valued at $6,202,000 after purchasing an additional 18,273 shares in the last quarter. Spartan Planning & Wealth Management purchased a new stake in Danaher during the third quarter valued at about $204,000. Finally, Lineweaver Wealth Advisors LLC bought a new stake in Danaher during the third quarter worth about $7,395,000. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Key Headlines Impacting Danaher Here are the key news stories impacting Danaher this week:

Positive Sentiment: AI partnership with NVIDIA: Danaher announced a collaboration to combine its scientific instruments, laboratory automation, workflow software and industry expertise with NVIDIA’s accelerated computing and AI technologies. The initiative is intended to advance autonomous science and speed scientific discovery, supporting Danaher’s long-term growth outlook in life-science tools and laboratory automation. Danaher Collaborates with NVIDIA to Advance Autonomous Science Positive Sentiment: Potential earnings beat: Zacks reports that Danaher has a strong history of exceeding quarterly estimates and currently has favorable Earnings ESP and consensus-estimate trends, raising expectations for another beat in its upcoming report. The company previously exceeded estimates with quarterly earnings of $1.94 per share versus a $1.85 consensus, while revenue rose 5.5% year over year. Will Danaher Beat Estimates Again in Its Next Earnings Report? Positive Sentiment: Longer-term automation opportunity: Danaher’s planned AI-powered autonomous laboratory, targeted for commercial-scale operation in early 2027, gives investors a potential future growth catalyst. The NVIDIA relationship could strengthen Danaher’s position as laboratories adopt AI and physical automation. How to Invest in AI Drug Discovery Neutral Sentiment: Analyst support: Morgan Stanley maintained a $240 price target, implying continued confidence in Danaher’s prospects, although the unchanged target provides no new upgrade catalyst. Morgan Stanley Keeps $240 Target for Danaher Stock Neutral Sentiment: Board changes: Danaher expanded its board to 13 members and appointed new directors, a governance development with limited immediate earnings or valuation impact. Danaher Enhances Board With New Director Appointments Wall Street Analyst Weigh In Several equities research analysts have issued reports on the company. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and set a $240.00 price target on shares of Danaher in a research note on Wednesday, July 22nd. Barclays increased their price objective on Danaher from $230.00 to $255.00 and gave the company an “overweight” rating in a research report on Wednesday, October 7th. Wall Street Zen raised Danaher from a “hold” rating to a “buy” rating in a report on Saturday, October 10th. Stifel Nicolaus decreased their price objective on Danaher from $260.00 to $220.00 and set a “buy” rating on the stock in a report on Wednesday, July 22nd. Finally, Weiss Ratings upgraded Danaher from a “hold (c-)” rating to a “hold (c)” rating in a research report on Wednesday, September 16th. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat.com, Danaher has a consensus rating of “Moderate Buy” and a consensus target price of $235.41. View Our Latest Stock Report on DHR

Danaher Price Performance Shares of Danaher stock opened at $224.65 on Thursday. Danaher Corporation has a 52-week low of $160.93 and a 52-week high of $242.80. The stock has a market capitalization of $157.93 billion, a price-to-earnings ratio of 39.90, a price-to-earnings-growth ratio of 2.80 and a beta of 0.76. The company has a fifty day moving average of $212.92 and a 200-day moving average of $195.39. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.25 and a current ratio of 1.65.

Danaher (NYSE:DHR – Get Free Report) last released its earnings results on Monday, July 20th. The conglomerate reported $1.94 EPS for the quarter, beating the consensus estimate of $1.85 by $0.09. The company had revenue of $6.26 billion for the quarter, compared to analyst estimates of $6.12 billion. Danaher had a net margin of 15.95% and a return on equity of 11.04%. The firm’s quarterly revenue was up 5.5% compared to the same quarter last year. During the same quarter last year, the firm earned $0.77 EPS. Equities research analysts expect that Danaher Corporation will post 8.53 EPS for the current year.

Danaher Announces Dividend The firm also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be paid a $0.40 dividend. The ex-dividend date of this dividend is Wednesday, September 30th. This represents a $1.60 annualized dividend and a yield of 0.7%. Danaher’s payout ratio is currently 28.42%.

Danaher Company Profile (Free Report)

Danaher Corporation (NYSE: DHR) is a global science and technology company that develops and manufactures products, services and solutions for the life sciences, diagnostics and biotechnology industries. Its offerings help researchers, healthcare professionals and biopharmaceutical manufacturers discover, develop, produce and analyze medicines and other biological products.

The company operates through businesses that provide laboratory instruments, consumables, software and services, including technologies for cell analysis, genomics, protein research, bioprocessing and clinical diagnostics.

See Also Five stocks we like better than Danaher Tesla Wants to Make Its Own Chips—What Could Go Wrong? IREN Limited’s AI Pivot Gains Traction—But Can Its Data Centers Deliver? PBF Energy’s Stunning Rally Faces a Critical Test Citi Stock Falls Despite Earnings Beat: What Investors Need to Know

Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.

Finward Bancorp purchased a new stake in shares of Danaher Corporation (NYSE:DHR – Free Report) in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 7,724 shares of the conglomerate’s stock, valued at approximately $1,711,000. Danaher comprises about 1.2% of Finward Bancorp’s investment portfolio, making the stock its 23rd largest position.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Columbus Macro LLC bought a new position in Danaher in the 3rd quarter valued at $5,213,000. Virginia Wealth Management Group Inc. bought a new position in shares of Danaher in the third quarter worth about $12,484,000. Union Savings Bank raised its stake in shares of Danaher by 258.6% in the third quarter. Union Savings Bank now owns 7,883 shares of the conglomerate’s stock worth $1,746,000 after acquiring an additional 5,685 shares during the last quarter. Elmwood Wealth Management Inc. raised its stake in shares of Danaher by 73.2% in the third quarter. Elmwood Wealth Management Inc. now owns 9,986 shares of the conglomerate’s stock worth $2,212,000 after acquiring an additional 4,222 shares during the last quarter. Finally, Essex LLC acquired a new position in shares of Danaher during the third quarter worth approximately $4,692,000. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Danaher Trading Up 0.8% DHR opened at $224.65 on Thursday. The firm has a 50 day simple moving average of $212.92 and a 200 day simple moving average of $195.39. Danaher Corporation has a fifty-two week low of $160.93 and a fifty-two week high of $242.80. The company has a market cap of $157.93 billion, a price-to-earnings ratio of 39.90, a price-to-earnings-growth ratio of 2.80 and a beta of 0.76. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.65 and a quick ratio of 1.25.

Danaher (NYSE:DHR – Get Free Report) last announced its quarterly earnings data on Monday, July 20th. The conglomerate reported $1.94 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.85 by $0.09. Danaher had a net margin of 15.95% and a return on equity of 11.04%. The firm had revenue of $6.26 billion for the quarter, compared to analysts’ expectations of $6.12 billion. During the same period last year, the firm earned $0.77 earnings per share. The business’s revenue for the quarter was up 5.5% on a year-over-year basis. On average, sell-side analysts anticipate that Danaher Corporation will post 8.53 earnings per share for the current year. Danaher Dividend Announcement The business also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be paid a $0.40 dividend. The ex-dividend date of this dividend is Wednesday, September 30th. This represents a $1.60 dividend on an annualized basis and a dividend yield of 0.7%. Danaher’s dividend payout ratio is 28.42%.

Analyst Ratings Changes Several research firms have recently commented on DHR. Deutsche Bank Aktiengesellschaft reissued a “buy” rating and set a $240.00 price target on shares of Danaher in a research note on Wednesday, July 22nd. Evercore restated an “outperform” rating and issued a $230.00 price objective on shares of Danaher in a research report on Monday, July 6th. TD Cowen boosted their price objective on shares of Danaher from $236.00 to $255.00 and gave the stock a “buy” rating in a research report on Tuesday. Guggenheim upped their price objective on Danaher from $200.00 to $250.00 and gave the stock a “buy” rating in a report on Thursday, October 1st. Finally, Morgan Stanley increased their price objective on Danaher from $220.00 to $240.00 and gave the company an “overweight” rating in a research report on Monday. Two analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $235.41.

View Our Latest Report on DHR

Key Danaher News Here are the key news stories impacting Danaher this week:

Positive Sentiment: AI partnership with NVIDIA: Danaher announced a collaboration to combine its scientific instruments, laboratory automation, workflow software and industry expertise with NVIDIA’s accelerated computing and AI technologies. The initiative is intended to advance autonomous science and speed scientific discovery, supporting Danaher’s long-term growth outlook in life-science tools and laboratory automation. Danaher Collaborates with NVIDIA to Advance Autonomous Science Positive Sentiment: Potential earnings beat: Zacks reports that Danaher has a strong history of exceeding quarterly estimates and currently has favorable Earnings ESP and consensus-estimate trends, raising expectations for another beat in its upcoming report. The company previously exceeded estimates with quarterly earnings of $1.94 per share versus a $1.85 consensus, while revenue rose 5.5% year over year. Will Danaher Beat Estimates Again in Its Next Earnings Report? Positive Sentiment: Longer-term automation opportunity: Danaher’s planned AI-powered autonomous laboratory, targeted for commercial-scale operation in early 2027, gives investors a potential future growth catalyst. The NVIDIA relationship could strengthen Danaher’s position as laboratories adopt AI and physical automation. How to Invest in AI Drug Discovery Neutral Sentiment: Analyst support: Morgan Stanley maintained a $240 price target, implying continued confidence in Danaher’s prospects, although the unchanged target provides no new upgrade catalyst. Morgan Stanley Keeps $240 Target for Danaher Stock Neutral Sentiment: Board changes: Danaher expanded its board to 13 members and appointed new directors, a governance development with limited immediate earnings or valuation impact. Danaher Enhances Board With New Director Appointments Danaher Profile (Free Report)

Danaher Corporation (NYSE: DHR) is a global science and technology company that develops and manufactures products, services and solutions for the life sciences, diagnostics and biotechnology industries. Its offerings help researchers, healthcare professionals and biopharmaceutical manufacturers discover, develop, produce and analyze medicines and other biological products.

The company operates through businesses that provide laboratory instruments, consumables, software and services, including technologies for cell analysis, genomics, protein research, bioprocessing and clinical diagnostics.

Recommended Stories Five stocks we like better than Danaher Tesla Wants to Make Its Own Chips—What Could Go Wrong? IREN Limited’s AI Pivot Gains Traction—But Can Its Data Centers Deliver? PBF Energy’s Stunning Rally Faces a Critical Test Citi Stock Falls Despite Earnings Beat: What Investors Need to Know

Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.

Forvis Mazars Wealth Advisors LLC lessened its stake in shares of Danaher Corporation (NYSE:DHR – Free Report) by 44.3% in the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 6,078 shares of the conglomerate’s stock after selling 4,837 shares during the period. Forvis Mazars Wealth Advisors LLC’s holdings in Danaher were worth $1,347,000 at the end of the most recent quarter.

A number of other large investors have also recently modified their holdings of the company. EP Wealth Advisors LLC purchased a new position in shares of Danaher in the 2nd quarter valued at $3,807,000. Puzo Michael J purchased a new stake in shares of Danaher during the 2nd quarter worth $8,624,000. Madison Asset Management LLC purchased a new stake in shares of Danaher during the 2nd quarter worth $85,451,000. First Nebraska Trust Co bought a new stake in Danaher during the second quarter valued at about $14,106,000. Finally, Colton Groome Financial Advisors LLC purchased a new position in Danaher in the third quarter valued at about $592,000. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Danaher Stock Performance Shares of Danaher stock opened at $223.30 on Wednesday. The company has a 50 day moving average price of $212.41 and a 200 day moving average price of $195.13. The firm has a market capitalization of $156.98 billion, a P/E ratio of 39.66, a PEG ratio of 2.78 and a beta of 0.76. The company has a quick ratio of 1.25, a current ratio of 1.65 and a debt-to-equity ratio of 0.48. Danaher Corporation has a 52 week low of $160.93 and a 52 week high of $242.80.

Danaher (NYSE:DHR – Get Free Report) last released its earnings results on Monday, July 20th. The conglomerate reported $1.94 earnings per share for the quarter, topping the consensus estimate of $1.85 by $0.09. Danaher had a net margin of 15.95% and a return on equity of 11.04%. The company had revenue of $6.26 billion for the quarter, compared to the consensus estimate of $6.12 billion. During the same quarter in the previous year, the firm earned $0.77 EPS. Danaher’s revenue was up 5.5% compared to the same quarter last year. Sell-side analysts expect that Danaher Corporation will post 8.53 EPS for the current year. Danaher Announces Dividend The company also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be given a $0.40 dividend. This represents a $1.60 annualized dividend and a dividend yield of 0.7%. The ex-dividend date of this dividend is Wednesday, September 30th. Danaher’s dividend payout ratio is presently 28.42%.

Analyst Upgrades and Downgrades Several analysts have commented on DHR shares. Wall Street Zen raised shares of Danaher from a “hold” rating to a “buy” rating in a research report on Saturday. Royal Bank Of Canada raised their target price on shares of Danaher from $215.00 to $250.00 and gave the company an “outperform” rating in a research note on Monday, October 5th. UBS Group assumed coverage on shares of Danaher in a report on Wednesday, September 9th. They issued a “buy” rating and a $250.00 price target on the stock. TD Cowen upped their price target on Danaher from $236.00 to $255.00 and gave the stock a “buy” rating in a research report on Tuesday. Finally, Guggenheim increased their price objective on Danaher from $200.00 to $250.00 and gave the company a “buy” rating in a report on Thursday, October 1st. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and four have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, Danaher presently has a consensus rating of “Moderate Buy” and an average price target of $235.41.

Check Out Our Latest Research Report on DHR

Danaher Company Profile (Free Report)

Danaher Corporation (NYSE: DHR) is a global science and technology company that develops and manufactures products, services and solutions for the life sciences, diagnostics and biotechnology industries. Its offerings help researchers, healthcare professionals and biopharmaceutical manufacturers discover, develop, produce and analyze medicines and other biological products.

The company operates through businesses that provide laboratory instruments, consumables, software and services, including technologies for cell analysis, genomics, protein research, bioprocessing and clinical diagnostics.

Further Reading Five stocks we like better than Danaher A Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be? Could T-Mobile’s Satellite Competition Fears Create a Buying Opportunity? Surgical Precision, Sustainable Returns: Johnson & Johnson Secures Its Cash Flow Runway Tesla’s Robotaxi Lands in Paris—But Europe’s Real Fight Is Over Cheap EVs

Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.

Danaher (DHR - Free Report) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended September 2026. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.

The earnings report, which is expected to be released on October 21, might help the stock move higher if these key numbers are better than expectations. On the other hand, if they miss, the stock may move lower.

While the sustainability of the immediate price change and future earnings expectations will mostly depend on management's discussion of business conditions on the earnings call, it's worth handicapping the probability of a positive EPS surprise.

Zacks Consensus EstimateThis industrial and medical device maker is expected to post quarterly earnings of $1.92 per share in its upcoming report, which represents a year-over-year change of +1.6%.

Revenues are expected to be $6.55 billion, up 8.2% from the year-ago quarter.

Estimate Revisions TrendThe consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period.

Investors should keep in mind that an aggregate change may not always reflect the direction of estimate revisions by each of the covering analysts.

Price, Consensus and EPS Surprise

Earnings WhisperEstimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. Our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction) -- has this insight at its core.

The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.

Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP readings only.

A positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). Our research shows that stocks with this combination produce a positive surprise nearly 70% of the time, and a solid Zacks Rank actually increases the predictive power of Earnings ESP.

Please note that a negative Earnings ESP reading is not indicative of an earnings miss. Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and/or Zacks Rank of 4 (Sell) or 5 (Strong Sell).

How Have the Numbers Shaped Up for Danaher?For Danaher, the Most Accurate Estimate is higher than the Zacks Consensus Estimate, suggesting that analysts have recently become bullish on the company's earnings prospects. This has resulted in an Earnings ESP of +0.30%.

On the other hand, the stock currently carries a Zacks Rank of #2.

So, this combination indicates that Danaher will most likely beat the consensus EPS estimate.

Does Earnings Surprise History Hold Any Clue?While calculating estimates for a company's future earnings, analysts often consider to what extent it has been able to match past consensus estimates. So, it's worth taking a look at the surprise history for gauging its influence on the upcoming number.

For the last reported quarter, it was expected that Danaher would post earnings of $1.84 per share when it actually produced earnings of $1.94, delivering a surprise of +5.43%.

Over the last four quarters, the company has beaten consensus EPS estimates four times.

Bottom LineAn earnings beat or miss may not be the sole basis for a stock moving higher or lower. Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors. Similarly, unforeseen catalysts help a number of stocks gain despite an earnings miss.

That said, betting on stocks that are expected to beat earnings expectations does increase the odds of success. This is why it's worth checking a company's Earnings ESP and Zacks Rank ahead of its quarterly release. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.

Danaher appears a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release.

Expected Results of an Industry PlayerDanaher (DHR - Free Report) , another stock in the Zacks Medical Services industry, is expected to report earnings per share of $1.92 for the quarter ended September 2026. This estimate points to a year-over-year change of +1.6%. Revenues for the quarter are expected to be $6.55 billion, up 8.2% from the year-ago quarter.

The consensus EPS estimate for Danaher has remained unchanged over the last 30 days. However, a higher Most Accurate Estimate has resulted in an Earnings ESP of +0.30%.

This Earnings ESP, combined with its Zacks Rank #2 (Buy), suggests that Danaher will most likely beat the consensus EPS estimate. The company beat consensus EPS estimates in each of the trailing four quarters.

Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.

Wall Street watches a company's quarterly report closely to understand as much as possible about its recent performance and what to expect going forward. Of course, one figure often stands out among the rest: earnings.

Life and the stock market are both about expectations, and rising above what is expected is often rewarded, while falling short can come with negative consequences. Investors might want to try to capture stronger returns by finding positive earnings surprises.

Hunting for 'earnings whispers' or companies poised to beat their quarterly earnings estimates is a somewhat common practice. But that doesn't make it easy. One way that has been proven to work is by using the Zacks Earnings ESP tool.

The Zacks Earnings ESP, ExplainedThe Zacks Earnings ESP, or Expected Surprise Prediction, aims to find earnings surprises by focusing on the most recent analyst revisions. The basic premise is that if an analyst reevaluates their earnings estimate ahead of an earnings release, it means they likely have new information that could possibly be more accurate.

Now that we understand the basic idea, let's look at how the Expected Surprise Prediction works. The ESP is calculated by comparing the Most Accurate Estimate to the Zacks Consensus Estimate, with the percentage difference between the two giving us the Zacks ESP figure.

In fact, when we combined a Zacks Rank #3 (Hold) or better and a positive Earnings ESP, stocks produced a positive surprise 70% of the time. Perhaps most importantly, using these parameters has helped produce 28.3% annual returns on average, according to our 10 year backtest.

Most stocks, about 60%, fall into the #3 (Hold) category, and they are expected to perform in-line with the broader market. Stocks with a #2 (Buy) and #1 (Strong Buy) rating, or the top 15% and top 5% of stocks, respectively, should outperform the market, with Strong Buy stocks outperforming more than any other rank.

Should You Consider Regeneron?The last thing we will do today, now that we have a grasp on the ESP and how powerful of a tool it can be, is to quickly look at a qualifying stock. Regeneron (REGN - Free Report) holds a #3 (Hold) at the moment and its Most Accurate Estimate comes in at $15.96 a share 16 days away from its upcoming earnings release on October 30, 2026.

REGN has an Earnings ESP figure of +0.23%, which, as explained above, is calculated by taking the percentage difference between the $15.96 Most Accurate Estimate and the Zacks Consensus Estimate of $15.93. Regeneron is one of a large database of stocks with positive ESPs. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.

REGN is just one of a large group of Medical stocks with a positive ESP figure. Danaher (DHR - Free Report) is another qualifying stock you may want to consider.

Slated to report earnings on October 21, 2026, Danaher holds a #2 (Buy) ranking on the Zacks Rank, and its Most Accurate Estimate is $1.93 a share seven days from its next quarterly update.

For Danaher, the percentage difference between its Most Accurate Estimate and its Zacks Consensus Estimate of $1.92 is +0.30%.

REGN and DHR's positive ESP metrics may signal that a positive earnings surprise for both stocks is on the horizon.

Find Stocks to Buy or Sell Before They're ReportedUse the Zacks Earnings ESP Filter to turn up stocks with the highest probability of positively, or negatively, surprising to buy or sell before they're reported for profitable earnings season trading. Check it out here >>

Value Investment Professionals LLC purchased a new position in shares of Danaher Corporation (NYSE:DHR – Free Report) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 2,832 shares of the conglomerate’s stock, valued at approximately $627,000.

Several other hedge funds and other institutional investors have also made changes to their positions in DHR. BlackRock Inc. purchased a new stake in Danaher during the 2nd quarter worth approximately $10,492,520,000. Wellington Management Group LLP lifted its holdings in Danaher by 10.4% during the 2nd quarter. Wellington Management Group LLP now owns 16,316,834 shares of the conglomerate’s stock worth $3,108,031,000 after buying an additional 1,542,310 shares in the last quarter. Jupiter Topco LLC acquired a new stake in Danaher during the 2nd quarter worth approximately $1,456,317,000. Generation Investment Management LLP acquired a new stake in Danaher during the 2nd quarter worth approximately $1,287,949,000. Finally, Bank of America Corp DE purchased a new position in Danaher in the 2nd quarter valued at approximately $993,846,000. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Analyst Upgrades and Downgrades Several equities analysts have commented on the stock. Barclays boosted their price target on shares of Danaher from $230.00 to $255.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 7th. Stifel Nicolaus reduced their price objective on Danaher from $260.00 to $220.00 and set a “buy” rating on the stock in a research note on Wednesday, July 22nd. UBS Group started coverage on Danaher in a research note on Wednesday, September 9th. They issued a “buy” rating and a $250.00 price objective on the stock. Royal Bank Of Canada lifted their target price on Danaher from $215.00 to $250.00 and gave the company an “outperform” rating in a report on Monday, October 5th. Finally, TD Cowen lowered their target price on Danaher from $240.00 to $236.00 and set a “buy” rating for the company in a research note on Wednesday, July 22nd. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and four have issued a Hold rating to the company’s stock. According to MarketBeat, Danaher presently has an average rating of “Moderate Buy” and an average price target of $234.55.

Read Our Latest Analysis on DHR Danaher Stock Up 0.7% DHR stock opened at $221.26 on Tuesday. The company’s 50 day moving average price is $211.85 and its 200 day moving average price is $194.88. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.25 and a current ratio of 1.65. Danaher Corporation has a fifty-two week low of $160.93 and a fifty-two week high of $242.80. The firm has a market capitalization of $155.54 billion, a price-to-earnings ratio of 39.30, a PEG ratio of 2.74 and a beta of 0.76.

Danaher (NYSE:DHR – Get Free Report) last issued its earnings results on Monday, July 20th. The conglomerate reported $1.94 earnings per share for the quarter, beating the consensus estimate of $1.85 by $0.09. Danaher had a net margin of 15.95% and a return on equity of 11.04%. The firm had revenue of $6.26 billion for the quarter, compared to analysts’ expectations of $6.12 billion. During the same quarter last year, the company earned $0.77 earnings per share. The firm’s revenue was up 5.5% compared to the same quarter last year. On average, equities research analysts anticipate that Danaher Corporation will post 8.53 EPS for the current fiscal year.

Danaher Announces Dividend The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be given a $0.40 dividend. The ex-dividend date of this dividend is Wednesday, September 30th. This represents a $1.60 dividend on an annualized basis and a dividend yield of 0.7%. Danaher’s dividend payout ratio is currently 28.42%.

About Danaher (Free Report)

Danaher Corporation (NYSE: DHR) is a global science and technology company that develops and manufactures products, services and solutions for the life sciences, diagnostics and biotechnology industries. Its offerings help researchers, healthcare professionals and biopharmaceutical manufacturers discover, develop, produce and analyze medicines and other biological products.

The company operates through businesses that provide laboratory instruments, consumables, software and services, including technologies for cell analysis, genomics, protein research, bioprocessing and clinical diagnostics.

Featured Articles Five stocks we like better than Danaher Salesforce Just Got a Rare Double Upgrade—What Changed? OpenAI’s Revenue Scare Could Be a Big Opportunity for Investors China Still Dominates Rare Earths—These 3 U.S. Companies Could Benefit 3 REITs That May Win in a Higher Interest Rate Environment

Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.

CoreCap Advisors LLC raised its stake in shares of Danaher Corporation (NYSE:DHR – Free Report) by 1,807.3% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 13,790 shares of the conglomerate’s stock after buying an additional 13,067 shares during the quarter. CoreCap Advisors LLC’s holdings in Danaher were worth $3,055,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in DHR. Dickmeyer Boyce Financial Management Inc. bought a new position in shares of Danaher in the third quarter worth approximately $1,700,000. YHB Investment Advisors Inc. increased its position in shares of Danaher by 1.1% during the third quarter. YHB Investment Advisors Inc. now owns 92,497 shares of the conglomerate’s stock valued at $20,023,000 after acquiring an additional 993 shares in the last quarter. Titleist Asset Management LLC bought a new stake in shares of Danaher during the third quarter valued at approximately $1,028,000. Apella Capital LLC increased its holdings in shares of Danaher by 1,095.6% in the 3rd quarter. Apella Capital LLC now owns 34,816 shares of the conglomerate’s stock worth $7,713,000 after purchasing an additional 31,904 shares in the last quarter. Finally, Everhart Financial Group Inc. increased its holdings in shares of Danaher by 137.9% in the 3rd quarter. Everhart Financial Group Inc. now owns 4,351 shares of the conglomerate’s stock worth $964,000 after purchasing an additional 2,522 shares in the last quarter. 79.05% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth DHR has been the topic of a number of research analyst reports. Stifel Nicolaus lowered their price target on Danaher from $260.00 to $220.00 and set a “buy” rating on the stock in a report on Wednesday, July 22nd. Piper Sandler began coverage on shares of Danaher in a research note on Thursday, June 11th. They issued a “neutral” rating and a $200.00 price target for the company. Guggenheim lifted their target price on shares of Danaher from $200.00 to $250.00 and gave the stock a “buy” rating in a research report on Thursday, October 1st. TD Cowen decreased their target price on shares of Danaher from $240.00 to $236.00 and set a “buy” rating for the company in a research note on Wednesday, July 22nd. Finally, Deutsche Bank Aktiengesellschaft reissued a “buy” rating and set a $240.00 price target on shares of Danaher in a report on Wednesday, July 22nd. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and four have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $235.23.

Read Our Latest Stock Analysis on Danaher Danaher Stock Performance NYSE:DHR opened at $217.33 on Friday. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.25 and a current ratio of 1.65. The stock has a 50-day simple moving average of $210.88 and a two-hundred day simple moving average of $194.44. The firm has a market capitalization of $152.78 billion, a PE ratio of 38.60, a P/E/G ratio of 2.72 and a beta of 0.76. Danaher Corporation has a 52-week low of $160.93 and a 52-week high of $242.80.

Danaher (NYSE:DHR – Get Free Report) last posted its quarterly earnings data on Monday, July 20th. The conglomerate reported $1.94 earnings per share for the quarter, beating analysts’ consensus estimates of $1.85 by $0.09. Danaher had a return on equity of 11.04% and a net margin of 15.95%.The firm had revenue of $6.26 billion for the quarter, compared to analysts’ expectations of $6.12 billion. During the same period in the previous year, the firm earned $0.77 EPS. The business’s quarterly revenue was up 5.5% on a year-over-year basis. Analysts forecast that Danaher Corporation will post 8.53 EPS for the current year.

Danaher Dividend Announcement The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be paid a $0.40 dividend. The ex-dividend date of this dividend is Wednesday, September 30th. This represents a $1.60 dividend on an annualized basis and a dividend yield of 0.7%. Danaher’s dividend payout ratio is 28.42%.

Danaher Company Profile (Free Report)

Danaher Corporation (NYSE: DHR) is a global science and technology company that develops and manufactures products, services and solutions for the life sciences, diagnostics and biotechnology industries. Its offerings help researchers, healthcare professionals and biopharmaceutical manufacturers discover, develop, produce and analyze medicines and other biological products.

The company operates through businesses that provide laboratory instruments, consumables, software and services, including technologies for cell analysis, genomics, protein research, bioprocessing and clinical diagnostics.

Featured Stories Five stocks we like better than Danaher Want Private-Market Access to Kalshi and Polymarket? Try This ETF Levi’s Stock Dip Reveals Value Opportunity Despite Q3 Headwinds PepsiCo Stock Looks Poised to Bottom With High Yield, Deep Value Alphabet’s $1.8 Billion Black Hills Deal Powers AI Data Center Push

Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.